23695 Literatur neue Nummerierung CR - Amazon …...©Elsevier GmbH. Alle Rechte vorbehalten. Rémi...

©Elsevier GmbH. Alle Rechte vorbehalten.

Rémi C., Bausewein C.: TOP Medikamente in der Palliativmedizin 1.A., Elsevier 2019

Seite 1 von 39

Literaturnachweis

1. Kotlinska-Lemieszek, A., et al., Polypharmacy in Patients With Advanced Cancer and Pain:

A European Cross-sectional Study of 2282 Patients. J Pain Symptom Manage, 2014.

2. Duerden, M., T. Avery, and R. Payne, Polypharmacy and medicines optimisation: Making

it safe and sound 2013, London: The King's Fund.

3. Schwenzer, S. Der bundeseinheitliche Medikationsplan. 2017 [cited 2017 16.11.2017];

Available from:

https://www.akdae.de/Arzneimitteltherapie/AVP/Artikel/201701/011h/index.php.

4. Spinewine, A., et al., Appropriateness of use of medicines in elderly inpatients: qualitative study. British Medical Journal, 2005. 331(7522): p. 935.

5. Dean, B., et al., Causes of prescribing errors in hospital inpatients: a prospective study.

Lancet, 2002. 359(9315): p. 1373–8.

6. Atkinson, C. and S. Kirkham, Unlicensed uses for medication in a palliative care unit.

Palliative Medicine, 1999. 13: p. 145–152.

7. Todd, J. and A. Davies, Use of unlicensed medication in palliative medicine. Palliative

Medicine, 1999. 13: p. 466.

8. O'Doherty, C.A., et al., Drugs and syringe drivers: a survey of adult specialist palliative

care practice in the United Kingdom and Eire. Palliative Medicine, 2001. 15(2): p. 149–54.

9. Wilcock, A., et al., Drugs given by a syringe driver: a prospective multicentre survey of

palliative care services in the UK. Palliative Medicine, 2006. 20(7): p. 661–4.

10. Dickman, A., et al., Identification of drug combinations administered by continuous

subcutaneous infusion that require analysis for compatibility and stability. BMC

Palliative Care, 2017. 16: p. 22.

11. Nelson, K.A., et al., A prospective within-patient crossover study of continuous

intravenous and subcutaneous morphine for chronic cancer pain. Journal of Pain and

Symptom Management, 1997. 13: p. 262–267.

12. Watanabe, S., et al., A randomized double-blind crossover comparison of continuous and intermittent subcutaneous administration of opioid for cancer pain. Journal of

Palliative Medicine, 2008. 11(4): p. 570-4.

13. Anderson, S.L. and S.T. Shreve, Continuous subcutaneous infusion of opiates at end-of-

life. Annals of Pharmacotherapy, 2004. 38(6): p. 1015–23.

14. Fonzo-Christe, C., et al., Subcutaneous administration of drugs in the elderly: survey of

practice and systematic literature review. Palliative Medicine, 2005. 19(3): p. 208–19.

15. Noriega, O. and S. Arino-Blasco, Subcutaneous fluid and drug delivery: safe, efficient and

inexpensive. Vol. 25. 2015. 117-146.

16. BNF, in British National Formulary. 2011, British Medical Association and the Royal

Pharmaceutical Society of Great Britain: London. 17. NPSA (National Patient Safety Agency). Patient safety alert 20: Promoting safer use of

injectable medicines. 2007; Available from: www.npsa.nhs.uk/nrls/alerts-and-

directives/alerts/injectable-medicines/.

18. RKI, Prävention Gefäßkatheterassoziierter Infektionen - Empfehlung der Kommission für

Krankenhaushygiene und Infektionsprävention beim Robert Koch-Institut (RKI).

Bundesgesundheitsblatt

2002. 45: p. 907-924.

19. MP Davis, e.a., Pharmacogenetics and opioids, in Opioids in Cancer Pain. 2009, Oxford

University Press. p. 287-299.



Seite 2 von 39

20. Foinard, A., et al., Impact of physical incompatibility on drug mass flow rates: example of

furosemide-midazolam incompatibility. Ann Intensive Care, 2012. 2(1): p. 28.

21. Good, P.D., J.J. Schneider, and P.J. Ravenscroft, The compatibility and stability of midazolam and dexamethasone in infusion solutions. J Pain Symptom Manage, 2004.

27(5): p. 471-5.

22. Napp, Personal communication. 2010.

23. AKDÄ. Drug Safety Mail 2009-062: Die Gabe von Protonenpumpeninhibitoren kann die

präventiven Effekte von Clopidogrel bei Patienten mit akutem Koronarsyndrom

vermindern. Drug Safety Mail 2009 [cited 2017 09.03.2017].

24. Ege, I., et al., PÄD i.v. 3 ed. 2009, München: Zuckschwerdt Verlag.

25. Dawkins, L., et al., A randomized trial of winged Vialon cannulae and metal butterfly

needles. International Journal of Palliative Nursing, 2000. 6(3): p. 110–6.

26. Ross, J.R., et al., A prospective, within-patient comparison between metal butterfly needles and Teflon cannulae in subcutaneous infusion of drugs to terminally ill hospice

patients. Palliative Medicine, 2002. 16(1): p. 13–6.

27. Mitchell, K., et al., Incidence and causes for syringe driver site reactions in palliative

care: A prospective hospice-based study. Palliat Med, 2012. 26(8): p. 979-85.

28. Reymond, L., et al., The effect of dexamethasone on the longevity of syringe driver

subcutaneous sites in palliative care patients. Medical Journal of Australia, 2003.

178(10): p. 486–9.

29. Wang, W., Tolerability of hypertonic injectables. Vol. 490. 2015.

30. Binding Database., Skaggs School of Pharmacy and Pharmaceutical Sciences Binding Database. 2015: University of California-San Diego (UCSD) Skaggs School of Pharmacy

and Pharmaceutical Sciences, La Jolla, CA 92093, USA.

31. Gillman, P.K., Tricyclic antidepressant pharmacology and therapeutic drug interactions

updated. Br J Pharmacol, 2007. 151(6): p. 737-48.

32. Schulz, P., et al., Discrepancies between pharmacokinetic studies of amitriptyline.

Clinical Pharmacokinetics, 1985. 10(3): p. 257-68.

33. Sindrup, S.H., et al., Antidepressants in the treatment of neuropathic pain. Basic and

Clinical Pharmacology and Toxicology, 2005. 96(6): p. 399–409.

34. Ray, W.A., et al., Psychotropic drug use and the risk of hip fracture. New England Journal

of Medicine, 1987. 316: p. 363–369. 35. Zafonte, R., E.P. Elovic, and L. Lombard, Acute care management of post-TBI spasticity.

Journal of Head Trauma Rehabilitation, 2004. 19(2): p. 89–100.

36. Guelaud, C., et al., Baclofen therapy for chronic hiccup. European Respiratory Journal,

1995. 8: p. 235–237.

37. Ramirez, F.C. and D.Y. Graham, Treatment of intractable hiccup with baclofen: results of

a double-blind randomized, controlled, crossover study. American Journal of

Gastroenterology, 1992. 87: p. 1789–1791.

38. Kochak, G.M., et al., The pharmacokinetics of baclofen derived from intestinal infusion.

Clinical Pharmacology and Therapeutics, 1985. 38: p. 251–257.

39. CSM (Committee on Safety of Medicines and Medicines Control Agency), Reminder! Severe withdrawal reactions with baclofen can be prevented by gradual dose reduction.

Current Problems in Pharmacovigilance, 1997. 23(February): p. 6.

40. Su, W., et al., Reduced level of consciousness from baclofen in people with low kidney

function. British Medical Journal, 2009. 339: p. b4559.

41. Drozd, M., et al., Iron Therapy in Patients with Heart Failure and Iron Deficiency: Review

of Iron Preparations for Practitioners. Am J Cardiovasc Drugs, 2017. 17(3): p. 183-201.



Seite 3 von 39

42. Benke, D., et al., GABA A receptors as in vivo substrate for the anxiolytic action of

valerenic acid, a major constituent of valerian root extracts. Neuropharmacology, 2009.

56(1): p. 174-81. 43. Rudolph, U. and F. Knoflach, Beyond classical benzodiazepines: novel therapeutic

potential of GABAA receptor subtypes. Nat Rev Drug Discov, 2011. 10(9): p. 685-97.

44. Stahl, S., Anxiety disorders and anxiolytics, in Stahl's essential psychopharmacology :

neuroscientific basis and practical applications. . 2013, Cambridge University Press: USA.

p. 388-419.

45. Idzikowski, C., The pharmacology of human sleep, a work in progress? Curr Opin

Pharmacol, 2014. 14: p. 90-6.

46. Dias, B.G., et al., Towards new approaches to disorders of fear and anxiety. Curr Opin

Neurobiol, 2013. 23(3): p. 346-52.

47. Pecking, M., et al., Absolute bioavailability of midazolam after subcutaneous administration to healthy volunteers. Br J Clin Pharmacol, 2002. 54(4): p. 357-62.

48. Beigmohammadi, M.T., et al., Pharmacokinetics Alterations of Midazolam Infusion

versus Bolus Administration in Mechanically Ventilated Critically Ill Patients. Iran J Pharm

Res, 2013. 12(2): p. 483-8.

49. Scott, L.J., K.A. Lyseng-Williamson, and K.P. Garnock-Jones, Oromucosal midazolam: a

guide to its use in paediatric patients with prolonged acute convulsive seizures. CNS

Drugs, 2012. 26(10): p. 893-7.

50. Drover, D.R., Comparative pharmacokinetics and pharmacodynamics of short-acting

hypnosedatives: zaleplon, zolpidem and zopiclone. Clin Pharmacokinet, 2004. 43(4): p. 227-38.

51. Riss, J., et al., Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta

Neurol Scand, 2008. 118(2): p. 69-86.

52. ABDA, Modellprojekt Ambulanter Entzug Benzodiazepin-abhängiger Patienten in

Zusammenarbeit von Apotheker und Hausarzt. 2013, Bundesvereinigung Deutscher

Apothekerverbände (ABDA): Berlin.

53. NICE, Benzodiazepine and Z-drug withdrawal. Clinical Knowledge Summaries, 2015.

54. Kotlinska-Lemieszek, A., Should Midazolam Drug-Drug Interactions be of Concern to

Palliative Care Physicians? Drug Saf, 2013.

55. Grad, R., Benzodiazepines for insomnia in community-dwelling elderly: a review of benefit and risk. Journal of Family Practice, 1995. 41: p. 473–481.

56. Petrov, M.E., et al., Benzodiazepine (BZD) use in community-dwelling older adults:

Longitudinal associations with mobility, functioning, and pain. Arch Gerontol Geriatr,

2014. 59(2): p. 331-7.

57. Mancuso, C.E., M.G. Tanzi, and M. Gabay, Paradoxical reactions to benzodiazepines:

literature review and treatment options. Pharmacotherapy, 2004. 24(9): p. 1177-85.

58. Saias, T. and T. Gallarda, [Paradoxical aggressive reactions to benzodiazepine use: a

review]. Encephale, 2008. 34(4): p. 330-6.

59. Weinbroum, A.A., et al., The midazolam-induced paradox phenomenon is reversible by

flumazenil. Epidemiology, patient characteristics and review of the literature. Eur J Anaesthesiol, 2001. 18(12): p. 789-97.

60. Baldwin, D.S., et al., Benzodiazepines: risks and benefits. A reconsideration. J

Psychopharmacol, 2013. 27(11): p. 967-71.

61. Kaneishi, K., M. Kawabata, and T. Morita, Single-Dose Subcutaneous Benzodiazepines for

Insomnia in Patients With Advanced Cancer. J Pain Symptom Manage, 2015. 49(6): p. e1-

2.



Seite 4 von 39

62. Prof. Dr. D. Riemann, E.B., S. Cohrs, T. Crönlein, G. Hajak, E. Hertenstein, P. Klose, J.

Langhorst, G. Mayer, C. Nissen, T. Pollmächer, S. Rabstein, A. Schlarb, H. Sitter, H.-G.

Weeß, T. Wetter, K. Spiegelhalder, S3-Leitlinie Nicht erholsamer Schlaf/Schlafstörungen. Somnologie 2017. 21: p. 2–44.

63. Wilson, S.J., et al., British Association for Psychopharmacology consensus statement on

evidence-based treatment of insomnia, parasomnias and circadian rhythm disorders.

Journal of Psychopharmacology, 2010. 24(11): p. 1577-601.

64. Foster, S., et al., Efficacy of lorazepam and haloperidol for rapid tranquilization in the

psychiatric emergency room setting. International Clinical Psychopharmacology, 1997.

12: p. 175–179.

65. Ciais, J.F., et al., Using Sodium Oxybate (Gamma Hydroxybutyric Acid) for Deep Sedation

at the End of Life. J Palliat Med, 2015. 18(10): p. 822.

66. Alonso-Babarro, A., et al., At-home palliative sedation for end-of-life cancer patients. Palliat Med, 2010. 24(5): p. 486-92.

67. Chater, S., et al., Sedation for intractable distress in the dying - a survey of experts.


68. Cherny, N.I. and L. Radbruch, European Association for Palliative Care (EAPC)

recommended framework for the use of sedation in palliative care. Palliat Med, 2009.

23(7): p. 581-93.

69. Cowan, J. and D. Walsh, Terminal sedation in palliative medicine - definition and review

of the literature. Supportive Care in Cancer, 2001. 9: p. 403–407.

70. Ensor, B. and D. Cohen, Benchmarking benzodiazepines and antipsychotics in the last 24 hours of life. N Z Med J, 2012. 125(1355): p. 19-30.

71. Goncalves, F., A. Almeida, and S. Pereira, A Protocol for the Control of Agitation in

Palliative Care. Am J Hosp Palliat Care, 2016. 33(10): p. 948-951.

72. Mercadante, S., et al., Palliative sedation in patients with advanced cancer followed at

home: a prospective study. J Pain Symptom Manage, 2014. 47(5): p. 860-6.

73. Mercadante, S., et al., Palliative sedation in advanced cancer patients followed at home:

a retrospective analysis. J Pain Symptom Manage, 2012. 43(6): p. 1126-30.

74. Müller-Busch, H.C., I. Andres, and T. Jehser, Sedation in palliative care - a critical analysis

of 7 years experience. BMC Palliative Care, 2003. 2(1): p. 2.

75. Radha Krishna, L.K., V.J. Poulose, and C. Goh, The use of midazolam and haloperidol in cancer patients at the end of life. Singapore Med J, 2012. 53(1): p. 62-6.

76. Harris, D.G., et al., The use of crisis medication in the management of terminal

haemorrhage due to incurable cancer: a qualitative study. Palliat Med, 2011. 25(7): p.

691-700.

77. Simon, S.T., et al., Benzodiazepines for the relief of breathlessness in advanced

malignant and non-malignant diseases in adults. Cochrane Database Syst Rev, 2010(1):

p. CD007354.

78. Navigante, A.H., et al., Midazolam as adjunct therapy to morphine in the alleviation of

severe dyspnea perception in patients with advanced cancer. Journal of Pain and

Symptom Management, 2006. 31(1): p. 38–47. 79. Rosenow, F., ed. Status epilepticus im Erwachsenealter. Leitlinien für Diagnostik und

Therapie in der Neurologie, ed. D.G.f. Neurologie. Vol. AWMF Registernummer 030/079.

2012.

80. Elger, C.E. and R. Berkenfeld, eds. S1 Leitlinie Erster epileptischer Anfall und Epilepsien

im Erwachsenenalter. Leitlinien für Diagnostik und Therapie in der Neurologie, ed. D.G.f.

Neurologie. 2017.



Seite 5 von 39

81. McKee, H.R. and B. Abou-Khalil, Outpatient pharmacotherapy and modes of

administration for acute repetitive and prolonged seizures. CNS Drugs, 2015. 29(1): p.

55-70. 82. Feddersen, B., Rémi, J., Noachtar, S. et al. , Epileptische Anfälle und Status epilepticus

bei Palliativpatienten. DNP Der Neurologe und Psychater, 2017. 18(3): p. 5-62.

83. Remi, C., et al., Continuous subcutaneous use of levetiracetam: a retrospective review of

tolerability and clinical effects. J Pain Palliat Care Pharmacother, 2014. 28(4): p. 371-7.

84. Lopez-Saca, J.M., et al., Repeated use of subcutaneous levetiracetam in a palliative care

patient. J Pain Symptom Manage, 2013. 45(5): p. e7-8.

85. Remi, C., V. Zwanzig, and B. Feddersen, Subcutaneous Use of Lacosamide. J Pain

Symptom Manage, 2016. 51(2): p. e2-4.

86. Aurora, R.N., et al., The treatment of restless legs syndrome and periodic limb

movement disorder in adults--an update for 2012: practice parameters with an evidence-based systematic review and meta-analyses: an American Academy of Sleep

Medicine Clinical Practice Guideline. Sleep, 2012. 35(8): p. 1039-62.

87. Garcia-Borreguero, D., et al., European guidelines on management of restless legs

syndrome: report of a joint task force by the European Federation of Neurological

Societies, the European Neurological Society and the European Sleep Research Society.

Eur J Neurol, 2012. 19(11): p. 1385-96.

88. Mackie, S. and J.W. Winkelman, Long-Term Treatment of Restless Legs Syndrome (RLS):

An Approach to Management of Worsening Symptoms, Loss of Efficacy, and

Augmentation. CNS Drugs, 2015. 29(5): p. 351-7. 89. Bartusch, S., et al., Clonazepam for the treatment of lancinating phantom limb pain.

Clinical Journal of Pain, 1996. 12: p. 59–62.

90. Bouckoms, A.J. and R.E. Litman, Clonazepam in the treatment of neuralgic pain

syndrome. Psychosomatics, 1985. 26(12): p. 933-6.

91. Hugel, H., J.E. Ellershaw, and A. Dickman, Clonazepam as an adjuvant analgesic in

patients with cancer-related neuropathic pain. Journal of Pain and Symptom

Management, 2003. 26(6): p. 1073-4.

92. Swerdlow, M. and J. Cundill, Anticonvulsant drugs used in the treatment of lancinating

pain: a comparison. Anaesthesia, 1981. 36: p. 1129–1132.

93. Chou, R. and L.H. Huffman, Nonpharmacologic therapies for acute and chronic low back pain: a review of the evidence for an American Pain Society/American College of

Physicians clinical practice guideline. Ann Intern Med, 2007. 147(7): p. 492-504.

94. Chou, R. and L.H. Huffman, Medications for acute and chronic low back pain: a review of

the evidence for an American Pain Society/American College of Physicians clinical

practice guideline. Ann Intern Med, 2007. 147(7): p. 505-14.

95. Moro, C., et al., Midazolam for long-term treatment of intractable hiccup. J Pain

Symptom Manage, 2005. 29(3): p. 221-3.

96. Cole, S.G., S. Brozinsky, and J.I. Isenberg, Midazolam, a new more potent

benzodiazepine, compared with diazepam: a randomized, double-blind study of

preendoscopic sedatives. Gastrointest Endosc, 1983. 29(3): p. 219-22. 97. Whitwam, J.G., D. Al-Khudhairi, and R.F. McCloy, Comparison of midazolam and

diazepam in doses of comparable potency during gastroscopy. Br J Anaesth, 1983. 55(8):

p. 773-7.

98. AHFS, M.G. AHFS Drug Information (online edition). 2017; Available from:

www.medicinescomplete.com/mc/ahfs/current/.



Seite 6 von 39

99. UK Medicines Information, What are the equivalent doses of oral benzodiazepines?

Medicines Q&As, 2018. 293.3.: p. www.evidence.nhs.uk.

100. Greenblatt, D.J., et al., Pharmacokinetic comparison of sublingual lorazepam with intravenous, intramuscular, and oral lorazepam. Journal of Pharmaceutical Sciences,

1982. 71(2): p. 248-52.

101. Caille, G., et al., Pharmacokinetics of two lorazepam formulations, oral and

sublingual, after multiple doses. Biopharmaceutics and Drug Disposition, 1983. 4(1): p.

31-42.

102. Gram-Hansen, P. and A. Schultz, Plasma concentrations following oral and

sublingual administration of lorazepam. International Journal of Clinical Pharmacology

Therapy and Toxicology, 1988. 26(6): p. 323-4.

103. Spenard, J., et al., Placebo-controlled comparative study of the anxiolytic activity

and of the pharmacokinetics of oral and sublingual lorazepam in generalized anxiety. Biopharmaceutics and Drug Disposition, 1988. 9: p. 457–464.

104. Nicholson, A. Lorazepam. Bulletin board 2007; Available from:

www.palliativedrugs.org/forum/read.php?f=1&i=11203&t=11203.

105. Moulin, D., et al., Comparisons of continuous subcutaneous and intravenous

hydromorphone infusion for management of cancer pain. Lancet, 1991. 337: p. 465–

468.

106. Schneider, J.J., P. Good, and P.J. Ravenscroft, Effect of tubing on loss of clonazepam

administered by continuous subcutaneous infusion. Journal of Pain and Symptom

Management, 2006. 31(6): p. 563–7. 107. Crosby, V., A. Wilcock, and R. Corcoran, A randomized controlled trial of

intravenous clodronate. Journal of Pain and Symptom Management, 1998. 15: p. 266–

268.

108. Harada, H., et al., Effects of bisphosphonates on joint damage and bone loss in rat

adjuvant-induced arthritis. Inflammation Research, 2004. 53(2): p. 45–52.

109. Saunders, Y., et al., Systematic review of bisphosphonates for hypercalcaemia of

malignancy. Palliative Medicine, 2004. 18(5): p. 418–31.

110. Wong, R. and P.J. Wiffen, Bisphosphonates for the relief of pain secondary to bone

metastases. Cochrane Database Systematic Reviews, 2002. 2: p. CD002068.

111. Rogers, M.J., et al., Cellular and molecular mechanisms of action of bisphosphonates. Cancer, 2000. 88 (suppl 12)(12 Suppl): p. 2961–78.

112. Barrett, J., et al., Ibandronate: a clinical pharmacological and pharmacokinetic

update. Journal of Clinical Pharmacology, 2004. 44(9): p. 951–65.

113. Broadbent, A., P. Glare, and B. Crawford, Bisphosphonate-induced hypocalcemia

associated with vitamin D deficiency in a patient with advanced cancer. American

Journal of Hospice and Palliative Care, 2005. 22(5): p. 382–4.

114. Johnson, M. and M. Fallon, Symptomatic hypocalcaemia with oral clodronate.

Journal of Pain and Symptom Management, 1998. 15: p. 140–142.

115. Tanvetyanon, T. and P.J. Stiff, Management of the adverse effects associated with

intravenous bisphosphonates. Annals of Oncology, 2006. 17(6): p. 897–907. 116. West, H., Denosumab for prevention of skeletal-related events in patients with

bone metastases from solid tumors: incremental benefit, debatable value. Journal of

Clinical Oncology, 2011. 29(9): p. 1095-8.

117. Ruggiero, S.L., et al., Osteonecrosis of the jaws associated with the use of

bisphosphonates: a review of 63 cases. Journal of Oral and Maxillofacial Surgery, 2004.

62(5): p. 527–34.



Seite 7 von 39

118. Diesinger C, H.L., Osteonekrosen des Kiefers und Osteonekrosen des äußeren

Gehörgangs unter der Therapie mit Bisphosphonaten oder Denosumab – neue

risikominimierende Maßnahmen. Bulletin zur Arzneimittelsicherheit, 2015. 6(4): p. 3-9. 119. Ärzteschaft), A.A.d.d., Osteonekrosen des Kieferknochens und des äußeren

Gehörgangs unter Therapie mit Bisphosphonaten und Denosumab („UAW-News

International“). . Deutsches Ärzteblatt, 2016. 113(19).

120. Fraunfelder, F.W. and F.T. Fraunfelder, Bisphosphonates and ocular inflammation.

N Engl J Med, 2003. 348(12): p. 1187–8.

121. Warr D, etc, and Etc. Use of biphosphonates in women with breast cancer. Practice

guideline report #1-11. Cancer Care Ontario program in evidence-based care. 2004;

Available from: www.cancercare.on.ca/common/pages/UserFile.aspx?fiIeld=34182.

122. SIGN (Scottish Intercollegiate Guidelines Network), Management of breast cancer in

women. A national clinical guideline. 2005, Edinburgh (Scotland): SIGN publication. 123. Vinholes, J., et al., Metabolic effects of pamidronate in patients with metastatic

bone disease. British Journal of Cancer, 1996. 73(3): p. 1089–1095.

124. Mannix, K., et al., Using bisphosphonates to control the pain of bone metastases:

evidence-based guidelines for palliative care. Palliative Medicine, 2000. 14: p. 455–461.

125. Rothman, R., Buprenorphine: a review of the binding literature., in Buprenorphine:

combatting drug abuse with a unique opioid., A. Cowan and J. Lewis, Editors. 1995,

Wiley-Liss: New York. p. 19–29.

126. Zaki, P., et al., Ligand-induced changes in surface mu-opioid receptor number:

relationship to G protein activation? Journal of Pharmacology and Experimental Therapeutics, 2000. 292(3): p. 1127–1134.

127. Lewis, J.W. and S.M. Husbands, The orvinols and related opioids--high affinity

ligands with diverse efficacy profiles. Current Pharmaceutical Design, 2004. 10(7): p.

717–32.

128. Ellis, R., et al., Pain relief after abdominal surgery-a comparison of i.m. morphine,

sublingual buprenorphine and self-administered i.v. pethidine. British Journal of

Anaesthesia, 1982. 54(4): p. 421–8.

129. Bullingham, R.E., et al., Mandatory sublingual buprenorphine for postoperative

pain. Anaesthesia, 1984. 39(4): p. 329–34.

130. Atkinson, R., P. Schofield, and P. Mellor, The efficacy in sequential use of buprenorphine and morphine in advanced cancer pain., in Opioids in the treatment of

cancer pain., D. Doyle, Editor. 1990, Royal Society of Medicine Services: London. p. 81–

87.

131. Cuschieri, R.J., C.G. Morran, and C.S. McArdle, Comparison of morphine and

sublingual buprenorphine following abdominal surgery. British Journal of Anaesthesia,

1984. 56(8): p. 855–9.

132. Sittl, R., R. Likar, and B.P. Nautrup, Equipotent doses of transdermal fentanyl and

transdermal buprenorphine in patients with cancer and noncancer pain: results of a

retrospective cohort study. Clinical Therapeutics, 2005. 27(2): p. 225–37.

133. Likar, R., B. Krainer, and R. Sittl, Challenging the equipotency calculation for transdermal buprenorphine: four case studies. International Journal of Clinical Practice,

2008. 62(1): p. 152–6.

134. Mercadante, S., et al., Equipotent doses to switch from high doses of opioids to

transdermal buprenorphine. Supportive Care in Cancer, 2009. 17(6): p. 715-8.



Seite 8 von 39

135. Caraceni, A., et al., Use of opioid analgesics in the treatment of cancer pain:

evidence-based recommendations from the EAPC. Lancet Oncology, 2012. 13(2): p. e58-

68. 136. Elkader, A. and B. Sproule, Buprenorphine: clinical pharmacokinetics in the

treatment of opioid dependence. Clinical Pharmacokinetics, 2005. 44(7): p. 661–80.

137. Heel, R.C., et al., Buprenorphine: a review of its pharmacological properties and

therapeutic efficiency. Drugs, 1979. 17: p. 81–110.

138. Robbie, D.S., A trial of sublingual buprenorphine in cancer pain. British Journal of

Clinical Pharmacology, 1979. 7 Suppl 3: p. S315–S317.

139. Johnson, R.E., P.J. Fudala, and R. Payne, Buprenorphine: considerations for pain

management. Journal of Pain and Symptom Management, 2005. 29(3): p. 297–326.

140. Malinoff, H.L., R.L. Barkin, and G. Wilson, Sublingual buprenorphine is effective in

the treatment of chronic pain syndrome. American Journal of Therapeutics, 2005. 12(5): p. 379–84.

141. Rosenblum, A., et al., Sublingual buprenorphine/naloxone for chronic pain in at-risk

patients: development and pilot test of a clinical protocol. Journal of Opioid

Management, 2012. 8(6): p. 369-82.

142. Boehringer Ingelheim GmbH, Data on file.

143. Tytgat, G.N., Hyoscine butylbromide: a review of its use in the treatment of

abdominal cramping and pain. Drugs, 2007. 67(9): p. 1343-57.

144. Sanches Martinez J, etc, and etc, Clinical assessment of the tolerability and the

effect of IK-19 in tablet form on pain of spastic origin. Investigacion Medica International, 1988. 15: p. 63-65.

145. Herxheimer, A. and L. Haefeli, Human pharmacology of hyoscine butylbromide.

Lancet, 1966. ii(August 20): p. 418–421.

146. Schuurkes, J.A.J., et al., Stimulation of gastroduodenal motor activity: dopaminergic

and cholinergic modulation. Drug Development Research, 1986. 8: p. 233–241.

147. Bennett, M., et al., Using anti-muscarinic drugs in the management of death rattle:

evidence based guidelines for palliative care. Palliative Medicine, 2002. 16: p. 369–374.

148. Castillo, P.E., et al., Endocannabinoid signaling and synaptic function. Neuron, 2012.

76(1): p. 70-81.

149. Hill, A.J., et al., Cannabidivarin is anticonvulsant in mouse and rat in vitro and in seizure models. British Journal of Pharmacology, 2012.

150. Preet, A., et al., Cannabinoid receptors, CB1 and CB2, as novel targets for inhibition

of non-small cell lung cancer growth and metastasis. Cancer Prev Res (Phila), 2011. 4(1):

p. 65-75.

151. Scotter, E.L., M.E. Abood, and M. Glass, The endocannabinoid system as a target for

the treatment of neurodegenerative disease. Br J Pharmacol, 2010. 160(3): p. 480-98.

152. Stanley, C.P., W.H. Hind, and S.E. O'Sullivan, Is the cardiovascular system a

therapeutic target for cannabidiol? British Journal of Clinical Pharmacology, 2013. 75(2):

p. 313-22.

153. Tanasescu, R. and C.S. Constantinescu, Cannabinoids and the immune system: an overview. Immunobiology, 2010. 215(8): p. 588-97.

154. Torres, S., et al., A combined preclinical therapy of cannabinoids and temozolomide

against glioma. Mol Cancer Ther, 2011. 10(1): p. 90-103.

155. Izzo, A.A., et al., Non-psychotropic plant cannabinoids: new therapeutic

opportunities from an ancient herb. Trends in Pharmacological Sciences, 2009. 30(10): p.

515-27.



Seite 9 von 39

156. Wilkerson, J.L., et al., Intrathecal cannabilactone CB(2)R agonist, AM1710, controls

pathological pain and restores basal cytokine levels. Pain, 2012. 153(5): p. 1091-106.

157. Gu, X., et al., Intrathecal administration of the cannabinoid 2 receptor agonist JWH015 can attenuate cancer pain and decrease mRNA expression of the 2B subunit of

N-methyl-D-aspartic acid. Anesth Analg, 2011. 113(2): p. 405-11.

158. Yu, X.H., et al., A peripherally restricted cannabinoid receptor agonist produces

robust anti-nociceptive effects in rodent models of inflammatory and neuropathic pain.

Pain, 2010. 151(2): p. 337-44.

159. Roques, B.P., M.C. Fournie-Zaluski, and M. Wurm, Inhibiting the breakdown of

endogenous opioids and cannabinoids to alleviate pain. Nat Rev Drug Discov, 2012.

11(4): p. 292-310.

160. Huggins, J.P., et al., An efficient randomised, placebo-controlled clinical trial with

the irreversible fatty acid amide hydrolase-1 inhibitor PF-04457845, which modulates endocannabinoids but fails to induce effective analgesia in patients with pain due to

osteoarthritis of the knee. Pain, 2012. 153(9): p. 1837-46.

161. Barnes, M.P., Sativex: clinical efficacy and tolerability in the treatment of symptoms

of multiple sclerosis and neuropathic pain. Expert Opinion on Pharmacotherpy, 2006.

7(5): p. 607–15.

162. Russo, E. and G.W. Guy, A tale of two cannabinoids: the therapeutic rationale for

combining tetrahydrocannabinol and cannabidiol. Medical Hypotheses, 2006. 66(2): p.

234-46.

163. Fusar-Poli, P., et al., Distinct effects of {delta}9-tetrahydrocannabinol and cannabidiol on neural activation during emotional processing. Archives of General

Psychiatry, 2009. 66(1): p. 95-105.

164. Grotenhermen, F., Pharmacokinetics and pharmacodynamics of cannabinoids.

Clinical Pharmacokinetics, 2003. 42(4): p. 327–360.

165. Malone, D.T., M.N. Hill, and T. Rubino, Adolescent cannabis use and psychosis:

epidemiology and neurodevelopmental models. Br J Pharmacol, 2010. 160(3): p. 511-22.

166. Simonetto, D.A., et al., Cannabinoid hyperemesis: a case series of 98 patients. Mayo

Clinic Proceedings, 2012. 87(2): p. 114-9.

167. Davis, M.P., Oral nabilone capsules in the treatment of chemotherapy-induced

nausea and vomiting and pain. Expert Opinion Investigational Drugs, 2008. 17(1): p. 85-95.

168. Farrell, M., R. Buchbinder, and W. Hall, Should doctors prescribe cannabinoids?

BMJ, 2014. 348: p. g2737.

169. Lynch, M.E. and F. Campbell, Cannabinoids for treatment of chronic non-cancer

pain; a systematic review of randomized trials. Br J Clin Pharmacol, 2011. 72(5): p. 735-

44.

170. Toth, C., et al., An enriched-enrolment, randomized withdrawal, flexible-dose,

double-blind, placebo-controlled, parallel assignment efficacy study of nabilone as

adjuvant in the treatment of diabetic peripheral neuropathic pain. Pain, 2012. 153(10):

p. 2073-82. 171. Langford, R.M., et al., A double-blind, randomized, placebo-controlled, parallel-

group study of THC/CBD oromucosal spray in combination with the existing treatment

regimen, in the relief of central neuropathic pain in patients with multiple sclerosis.

Journal of Neurology, 2013. 260(4): p. 984-97.



Seite 10 von 39

172. Wade, D.T., et al., Long-term use of a cannabis-based medicine in the treatment of

spasticity and other symptoms in multiple sclerosis. Multiple Sclerosis, 2006. 12(5): p.

639–45. 173. Nurmikko, T.J., et al., Sativex successfully treats neuropathic pain characterised by

allodynia: a randomised, double-blind, placebo-controlled clinical trial. Pain, 2007.

133(1-3): p. 210–20.

174. Johnson, J.R., et al., An Open-Label Extension Study to Investigate the Long-Term

Safety and Tolerability of THC/CBD Oromucosal Spray and Oromucosal THC Spray in

Patients With Terminal Cancer-Related Pain Refractory to Strong Opioid Analgesics.

Journal of Pain and Symptom Management, 2012.

175. CADTH, Nabilone for chronic pain management: a review of clinical efectiveness,

safety and guidelines. , in Canadian Agency for Drugs and Technologies in Health; Rapid

Response Report: summary with critical appraisal. 2011. 176. Hu, M.I., et al., Denosumab for treatment of hypercalcemia of malignancy. J Clin

Endocrinol Metab, 2014. 99(9): p. 3144-52.

177. Schwartz, J.I., et al., Comparative inhibitory activity of etoricoxib, celecoxib, and

diclofenac on COX-2 versus COX-1 in healthy subjects. Journal of Clinical Pharmacology,

2008. 48(6): p. 745-54.

178. Patrignani, P., et al., Differential inhibition of human prostaglandin endoperoxide

synthase-1 and -2 by nonsteroidal anti-inflammatory drugs. Journal of Physiology and

Pharmacology, 1997. 48: p. 623–631.

179. John, V., The pharmacokinetics and metabolism of diclofenac sodium (Voltarol) in animals and man. Rheumatology and Rehabilitation, 1979. (suppl 2): p. 22–37.

180. CNT Collaboration, Vascular and upper gastrointestinal effects of non-steroidal anti-

inflammatory drugs: meta-analyses of individual participant data from randomised trials.

Lancet, 2013: p. Published Online May 30, 2013 http://dx.doi.org/10.1016/S0140-

6736(13)60900-9.

181. Sondergaard, K.B., et al., Non-steroidal anti-inflammatory drug use is associated

with increased risk of out-of-hospital cardiac arrest: a nationwide case-time-control

study. Eur Heart J Cardiovasc Pharmacother, 2017. 3(2): p. 100-107.

182. Schneider, V., et al., Association of selective and conventional nonsteroidal

antiinflammatory drugs with acute renal failure: A population-based, nested case-control analysis. American Journal of Epidemiology, 2006. 164(9): p. 881–9.

183. Gladding, P.A., et al., The antiplatelet effect of six non-steroidal anti-inflammatory

drugs and their pharmacodynamic interaction with aspirin in healthy volunteers.

American Journal of Cardiology, 2008. 101(7): p. 1060-3.

184. Dundee, J. and P. Jones, The prevention of analgesic-induced nausea and vomiting

by cyclizine. British Journal of Clinical Practice, 1968. 22: p. 379–382.

185. Aitkenhead, A.R., et al., Pharmacokinetics of single dose IV morphine in normal

volunteers and patients with end-stage renal failure. British Journal of Anaesthesia,

1984. 56: p. 813–819.

186. Brandt, T., M. Dieterich, and M. Strupp, Vertigo - Leitsymptom Schwindel. Springer Medizin. Vol. 2. 2013, Berlin: Springer.

187. Bisdorff, A., et al., The epidemiology of vertigo, dizziness, and unsteadiness and its

links to co-morbidities. Front Neurol, 2013. 4: p. 29.

188. Karatas, M., Central vertigo and dizziness: epidemiology, differential diagnosis, and

common causes. Neurologist, 2008. 14(6): p. 355-64.



Seite 11 von 39

189. Baxter, K., Preston CL. Stockley's Drug Interactions. 2017; Available from:

www.medicinescomplete.com.

190. Bymaster, F.P., et al., Comparative affinity of duloxetine and venlafaxine for serotonin and norepinephrine transporters in vitro and in vivo, human serotonin

receptor subtypes, and other neuronal receptors. Neuropsychopharmacology, 2001.

25(6): p. 871–80.

191. Yamashita, T., et al., Duloxetine Inhibits Microglial P2X4 Receptor Function and

Alleviates Neuropathic Pain after Peripheral Nerve Injury. PLoS One, 2016. 11(10): p.

e0165189.

192. Cleare, A., et al., Evidence-based guidelines for treating depressive disorders with

antidepressants: A revision of the 2008 British Association for Psychopharmacology

guidelines. J Psychopharmacol, 2015. 29(5): p. 459-525.

193. Perahia, D.G., et al., The risk of bleeding with duloxetine treatment in patients who use nonsteroidal anti-inflammatory drugs (NSAIDs): analysis of placebo-controlled trials

and post-marketing adverse event reports. Drug Healthc Patient Saf, 2013. 5: p. 211-9.

194. Finnerup, N.B., et al., Pharmacotherapy for neuropathic pain in adults: a systematic

review and meta-analysis. Lancet Neurol, 2016. 14(2): p. 162-73.

195. DTB, Managing postpartum stress urinary incontinence. Drug and Therapeutics

Bulletin, 2003. 41(6): p. 46–8.

196. Reisenauer, C., et al., Interdisciplinary S2e Guideline for the Diagnosis and

Treatment of Stress Urinary Incontinence in Women: Short version - AWMF Registry No.

015-005, July 2013. Geburtshilfe Frauenheilkd, 2013. 73(9): p. 899-903. 197. Canneti, A., et al., Safety and efficacy of transdermal buprenorphine and

transdermal fentanyl in the treatment of neuropathic pain in AIDS patients. Minerva

Anestesiol, 2013. 79(8): p. 871-83.

198. Newshan, G. and M. Lefkowitz, Transdermal fentanyl for chronic pain in AIDS: a

pilot study. Journal of Pain and Symptom Management, 2001. 21: p. 69–77.

199. Tassinari, D., et al., Transdermal opioids as front line treatment of moderate to

severe cancer pain: a systemic review. Palliat Med, 2011. 25(5): p. 478-87.

200. King, S., et al., A systematic review of the use of opioid medication for those with

moderate to severe cancer pain and renal impairment: a European Palliative Care

Research Collaborative opioid guidelines project. Palliat Med, 2011. 25(5): p. 525-52. 201. Health Canada, Fentanyl transdermal patch and fatal adverse reactions. Canadian

Adverse Reaction Newsletter, 2008. 18(3): p. 1-2.

202. Herz, A. and H.-J. Teschemacher, Activities and sites of antinociceptive action of

morphine-like analgesics and kinetics of distribution following intravenous, intracerebral

and intraventricular application. Advances in Drug Research, 1971. 6: p. 79–119.

203. Heiskanen, T., et al., Transdermal fentanyl in cachectic cancer patients. Pain, 2009.

144(1-2): p. 218-22.

204. Hadgraft, J. and M.E. Lane, Skin permeation: the years of enlightenment.[see

comment]. International Journal of Pharmaceutics, 2005. 305(1-2): p. 2-12.

205. Gourlay, G.K., et al., The transdermal administration of fentanyl in the treatment of post-operative pain: pharmacokinetics and pharmacodynamic effects. Pain, 1989. 37: p.

193–202.

206. Capper, S.J., et al., Pharmacokinetics of fentanyl after subcutaneous administration

in volunteers. European Journal of Anaesthesiology, 2010. 27(3): p. 241-6.

207. Portenoy, R.K., et al., Transdermal fentanyl for cancer pain. Anesthesiology, 1993.

78: p. 36–43.



Seite 12 von 39

208. Smith, J. and J. Ellershaw, Improvement in pain control by change of fentanyl patch

after 48 hours compared with 72 hours. Poster EAPC Congress, Geneva, 1999: p.

PO1/1376. 209. Darwish, M., et al., Absolute and relative bioavailability of fentanyl buccal tablet

and oral transmucosal fentanyl citrate. Journal of Clinical Pharmacology, 2007. 47(3): p.

343–50.

210. European Medicines Agency, Assessment report for Pecfent. Procedure No.

EMA/H/C/001164. 2010.

211. Vasisht, N., et al., Single-dose pharmacokinetics of fentanyl buccal soluble film. Pain

Medicine, 2010. 11(7): p. 1017-23.

212. European Medicines Agency, Effentora: EPAR - Scientific discussion. 2008.

213. Lichtor, J., et al., The relative potency of oral transmucosal fentanyl citrate

compared with intravenous morphine in the treatment of moderate to severe postoperative pain. Anesthesia and Analgesia, 1999. 89: p. 732–738.

214. Finn, A.L., et al., Absorption and tolerability of fentanyl buccal soluble film (FBSF) in

patients with cancer in the presence of oral mucositis. Journal of Pain Research, 2011. 4:

p. 245-51.

215. FDA, Center for drug evaluation and research. Summary Review. Application

number 22-266. 2009.

216. Darwish, M., et al., Absorption of fentanyl from fentanyl buccal tablet in cancer

patients with or without oral mucositis: a pilot study. Clinical Drug Investigation, 2007.

27(9): p. 605–11. 217. Darwish, M., et al., Comparison of equivalent doses of fentanyl buccal tablets and

arteriovenous differences in fentanyl pharmacokinetics. Clinical Pharmacokinetics, 2006.

45(8): p. 843-50.

218. Kaasa, S., et al., Pharmacokinetics of intranasal fentanyl spray in patients with

cancer and breakthrough pain. Journal of Opioid Management, 2010. 6(1): p. 17-26.

219. European Medicines Agency, Assessment report for Instanyl. Procedure No.

EMEA/H/C/959. London. 2009.

220. Morii, H., et al., Failure of pain control using transdermal fentanyl during rifampicin

treatment. Journal of Pain and Symptom Management, 2007. 33(1): p. 5–6.

221. Sasson, M. and P. Shvartzman, Fentanyl patch sufficient analgesia for only one day. Journal of Pain and Symptom Management, 2006. 31(5): p. 389–91.

222. Takane, H., et al., Rifampin reduces the analgesic effect of transdermal fentanyl.

Annals of Pharmacotherpy, 2005. 39(12): p. 2139–40.

223. Kharasch, E.D., D. Whittington, and C. Hoffer, Influence of hepatic and intestinal

cytochrome P4503A activity on the acute disposition and effects of oral transmucosal

fentanyl citrate. Anesthesiology, 2004. 101(3): p. 729–37.

224. Janssen-Cilag Ltd, Data on file.

225. Freynhagen, R., et al., Switching from reservoir to matrix systems for the

transdermal delivery of fentanyl: a prospective, multicenter pilot study in outpatients

with chronic pain. Journal of Pain and Symptom Management, 2005. 30(3): p. 289–97. 226. Marier, J.F., et al., Pharmacokinetics, tolerability, and performance of a novel matrix

transdermal delivery system of fentanyl relative to the commercially available reservoir

formulation in healthy subjects. Journal of Clinical Pharmacology, 2006. 46(6): p. 642–

53.



Seite 13 von 39

227. Kress, H.G., et al., Transdermal fentanyl matrix patches Matrifen and Durogesic

DTrans are bioequivalent. European Journal of Pharmceutics and Biopharmaceutics,

2010. 75(2): p. 225-31. 228. Samala, R.V., R. Bloise, and M.P. Davis, Efficacy and safety of a six-hour continuous

overlap method for converting intravenous to transdermal fentanyl in cancer pain. J Pain

Symptom Manage, 2014. 48(1): p. 132-6.

229. Fine, P.G., et al., Long-term safety and tolerability of fentanyl buccal tablet for the

treatment of breakthrough pain in opioid-tolerant patients with chronic pain: an 18-

month study. Journal of Pain and Symptom Management, 2010. 40(5): p. 747-60.

230. Markman, J.D., Not so fast: the reformulation of fentanyl and breakthrough chronic

non-cancer pain. Pain, 2008. 136(3): p. 227-9.

231. Nunez-Olarte, J.M. and P. Alvarez-Jimenez, Emerging opioid abuse in terminal

cancer patients taking oral transmucosal fentanyl citrate for breakthrough pain. Journal of Pain and Symptom Management, 2011. 42(6): p. e6-8.

232. Passik, S.D., et al., Aberrant Drug-Related Behavior Observed During Clinical Studies

Involving Patients Taking Chronic Opioid Therapy for Persistent Pain and Fentanyl Buccal

Tablet for Breakthrough Pain. Journal of Pain and Symptom Management, 2011. 41: p.

116-125.

233. Christie, J., et al., Dose-titration, multicenter study of oral transmucosal fentanyl

citrate for the treatment of breakthrough pain in cancer patients using transdermal

fentanyl for persistent pain. Journal of Clinical Oncology, 1998. 16: p. 3238–3248.

234. Portenoy, R., et al., Oral transmucosal fentanyl citrate (OTFC) for the treatment of breakthrough pain in cancer patients: a controlled use titration study. Pain, 1999. 79: p.

303–312.

235. Portenoy, R.K., et al., A randomized, placebo-controlled study of fentanyl buccal

tablet for breakthrough pain in opioid-treated patients with cancer. Clinical Journal of

Pain, 2006. 22(9): p. 805–11.

236. Slatkin, N.E., et al., Fentanyl buccal tablet for relief of breakthrough pain in opioid-

tolerant patients with cancer-related chronic pain. Journal of Supportive Oncology,

2007. 5(7): p. 327–34.

237. Mercadante, S., et al., A comparison of intranasal fentanyl spray with oral

transmucosal fentanyl citrate for the treatment of breakthrough cancer pain: an open label, randomised, crossover trial. Current Medical Research Opinion, 2009. 25(11): p.

2805-15.

238. Ashburn, M.A., et al., The efficacy and safety of fentanyl buccal tablet compared

with immediate-release oxycodone for the management of breakthrough pain in opioid-

tolerant patients with chronic pain. Anesthesia and Analgesia, 2011. 112(3): p. 693-702.

239. Mercadante, S., G. Prestia, and A. Casuccio, The use of sublingual fentanyl for

breakthrough pain by using doses proportional to opioid basal regimen. Curr Med Res

Opin, 2013. 29(11): p. 1527-32.

240. Mercadante, S., et al., Fentanyl Buccal Tablet vs. Oral Morphine in Doses

Proportional to the Basal Opioid Regimen for the Management of Breakthrough Cancer Pain: A Randomized, Crossover, Comparison Study. J Pain Symptom Manage, 2015.

50(5): p. 579-86.

241. Shimoyama, N., et al., Efficacy and safety of sublingual fentanyl orally disintegrating

tablet at doses determined from oral morphine rescue doses in the treatment of

breakthrough cancer pain. Jpn J Clin Oncol, 2015. 45(2): p. 189-96.



Seite 14 von 39

242. Mercadante, S., et al., Fentanyl Pectin Nasal Spray Versus Oral Morphine in Doses

Proportional to the Basal Opioid Regimen for the Management of Breakthrough Cancer

Pain: A Comparative Study. J Pain Symptom Manage, 2016. 52(1): p. 27-34. 243. Darwish, M., et al., Bioequivalence following buccal and sublingual placement of

fentanyl buccal tablet 400 microg in healthy subjects. Clinical Drug Investigation, 2008.

28(1): p. 1–7.

244. Kremer, M., et al., Antidepressants and gabapentinoids in neuropathic pain:

Mechanistic insights. Neuroscience, 2016. 338: p. 183-206.

245. Gahr, M., et al., Pregabalin abuse and dependence in Germany: results from a

database query. Eur J Clin Pharmacol, 2013. 69(6): p. 1335-42.

246. Gahr, M., et al., Concerns about pregabalin: further experience with its potential of

causing addictive behaviors. J Addict Med, 2013. 7(2): p. 147-9.

247. Arzneimittelkommission der deutschen Ärzteschaft: Aus der UAW-Datenbank Abhängigkeitspotenzial von Pregabalin (Lyrica ® ). Dtsch Arztebl International, 2011.

108(4): p. 183.

248. Dworkin, R.H., et al., Pharmacologic management of neuropathic pain: evidence-

based recommendations.[see comment]. Pain, 2007. 132(3): p. 237-51.

249. Backonja, M. and R.L. Glanzman, Gabapentin dosing for neuropathic pain: evidence

from randomized, placebo-controlled clinical trials. Clinical Therapeutics, 2003. 25(1): p.

81–104.

250. Tremont-Lukats, I.W., P.R. Hutson, and M.M. Backonja, A randomized, double-

masked, placebo-controlled pilot trial of extended IV lidocaine infusion for relief of ongoing neuropathic pain. Clinical Journal of Pain, 2006. 22(3): p. 266-71.

251. Pandya, K.J., et al., Gabapentin for hot flashes in 420 women with breast cancer: a

randomised double-blind placebo-controlled trial. Lancet, 2005. 366(9488): p. 818–24.

252. Alonso-Navarro, H., L. Rubio, and F.J. Jimenez-Jimenez, Refractory hiccup:

successful treatment with gabapentin. Clinical Neuropharmacology, 2007. 30(3): p. 186–

7.

253. Moretti, R., et al., Gabapentin as a drug therapy of intractable hiccup because of

vascular lesion: a three-year follow up. Neurologist, 2004. 10(2): p. 102-6.

254. Freynhagen, R., et al., Efficacy of pregabalin in neuropathic pain evaluated in a 12-

week, randomised, double-blind, multicentre, placebo-controlled trial of flexible- and fixed-dose regimens. Pain, 2005. 115(3): p. 254–63.

255. Mirakhur, R. and J. Dundee, Glycopyrrolate pharmacology and clinical use.

Anaesthesia, 1983. 38: p. 1195–1204.

256. Grum, D. and L. Osborne, Central anticholinergic syndrome following

glycopyrrolate. Anesthesiology, 1991. 74: p. 191–193.

257. Wigard, D., Glycopyrrolate and the central anticholinergic syndrome (letter).

Anesthesiology, 1991. 75: p. 1125.

258. Mirakhur, R. and J. Dundee, A comparison of the effects of atropine and

glycopyrollate on various end organs. Journal of the Royal Society of Medicine, 1980. 73:

p. 727–730. 259. Ali-Melkkila, T., T. Kaila, and J. Kanto, Glycopyrrolate; pharmacokinetics and some

pharmacodynamics findings. Acta Anaesthesiologica Scandinavica, 1989. 33: p. 513–517.

260. Blasco, P., Glycopyrrolate treatment of chronic drooling. Archives of Paediatric and

Adolescent Medicine, 1996. 150: p. 932–935.

261. Olsen, A. and P. Sjogren, Oral glycopyrrolate alleviates drooling in a patient with

tongue cancer. Journal of Pain and Symptom Management, 1999. 18: p. 300–302.



Seite 15 von 39

262. Hughes, A., et al., Audit of three antimuscarinic drugs for managing retained

secretions. Palliative Medicine, 2000. 14: p. 221–222.

263. Rashid, H., J. Lond, and R. Wadleigh, Management of secretions in esophageal cancer patients with glycopyrrolate. Annals of Oncology, 1997. 8(2): p. 198–199.

264. Lucas, V. and C. Amass, Use of enteral glycopyrrolate in the management of

drooling. Palliative Medicine, 1998. 12: p. 207.

265. Davis, M. and A. Furste, Glycopyrrolate: a useful drug in the palliation of mechanical

bowel obstruction. Journal of Pain and Symptom Management, 1999. 18: p. 153–154.

266. Arbouw, M.E., et al., Glycopyrrolate for sialorrhea in Parkinson disease: a

randomized, double-blind, crossover trial. Neurology, 2010. 74(15): p. 1203-7.

267. Ondo, W.G., C. Hunter, and W. Moore, A double-blind placebo-controlled trial of

botulinum toxin B for sialorrhea in Parkinson's disease. Neurology, 2004. 62(1): p. 37-40.

268. Anonymous, Glycopyrrolate 0.5mg/mL oral liquid. International Journal of Pharmaceutical Compounding., 2004. 8: p. 218.

269. Landry C, etc, and etc, Stability and subjective taste acceptability of four

glycopyrrolate solutions for oral administration. International Journal of Pharmaceutical

Compounding., 2005. 9: p. 396-398.

270. Prommer, E., Role of haloperidol in palliative medicine: an update. Am J Hosp Palliat

Care, 2012. 29(4): p. 295-301.

271. Meagher, D.J., et al., What do we really know about the treatment of delirium with

antipsychotics? Ten key issues for delirium pharmacotherapy. Am J Geriatr Psychiatry,

2013. 21(12): p. 1223-38. 272. Kang, J.H., S.H. Shin, and E. Bruera, Comprehensive approaches to managing

delirium in patients with advanced cancer. Cancer Treat Rev, 2013. 39(1): p. 105-12.

273. Bush, S.H., et al., Treating an established episode of delirium in palliative care:

expert opinion and review of the current evidence base with recommendations for

future development. J Pain Symptom Manage, 2014. 48(2): p. 231-248.

274. Ives, T.J., et al., Treatment of intractable hiccups with intramuscular haloperidol.

American Journal of Psychiatry, 1985. 142: p. 1368–1369.

275. Scarnati, R.A., Intractable hiccup (singultus): report of case. Journal of the American

Osteopathic Association, 1979. 79(2): p. 127–129.

276. Thompson, D.F. and K.G. Brooks, Gabapentin therapy of hiccups. Ann Pharmacother, 2013. 47(6): p. 897-903.

277. Jatzko, A., A. Stegmeier-Petroianu, and G.A. Petroianu, Alpha-2-delta ligands for

singultus (hiccup) treatment: three case reports. J Pain Symptom Manage, 2007. 33(6):

p. 756-60.

278. Bao, Y.J., et al., Hydromorphone for cancer pain. Cochrane Database Syst Rev, 2016.

10: p. Cd011108.

279. Quigley C and Glare P, Hydromorphone, in Opioids in Cancer Pain, M. Davis, et al.,

Editors. 2009, Oxford University Press: Oxford. p. 245-252.

280. McDonald, C. and A. Miller, A comparative potency study of a controlled release

tablet formulation of hydromorphone with controlled release morphine in patients with cancer pain. European Journal of Palliative Care. Abstracts of the Fifth Congress., 1997.

281. Moriarty, M., C. McDonald, and A. Miller, A randomised crossover comparison of

controlled release hydromorphone tablets with controlled release morphine tablets in

patients with cancer pain. Journal of Clinical Research, 1999. 2: p. 1–8.

282. Medizinischen, L.O.d.A.d.W., D.K.e.V.D. Fachgesellschaften e. V. (AWMF), and

u.D.K. (DKH). eds. S3-Leitlinie Palliativmedizin für Patienten mit einer nicht-heilbaren



Seite 16 von 39

Tumorerkrankung. Leitlinienprogramm Onkologie. Vol. AWMF-Registernummer

128/001OL. 2015.

283. Mercadante, S. and A. Caraceni, Conversion ratios for opioid switching in the treatment of cancer pain: a systematic review. Palliat Med, 2011. 25(5): p. 504-15.

284. Vallner, J., et al., Pharmacokinetics and bioavailability of hydromorphone following

intravenous and oral administration to human subjects. Journal of Clinical

Pharmacology, 1981. 21: p. 152–156.

285. Coda, B., et al., Hydromorphone analgesia after intravenous bolus administration.

Pain, 1997. 71(1): p. 41-8.

286. Benedetti, C.B. and S.H. Butler, Systemic analgesics, in The Management of Pain,

Bonica J.J, Editor. 1990, Lea and Febiger: Philedelphia.

287. Durnin, C., et al., Pharmacokinetics of oral immediate-release hydromorphone

(Dilaudid IR) in young and elderly subjects. Proc West Pharmacol Soc, 2001. 44: p. 79-80. 288. Hagen, N., et al., Steady-state pharmacokinetics of hydromorphone and

hydromorphone-3-glucuronide in cancer patients after immediate and controlled-

release hydromorphone. Journal of Clinical Pharmacology, 1995. 35: p. 37–44.

289. Bruera, E., et al., A randomized, double-blind, double-dummy, crossover trial

comparing the safety and efficacy of oral sustained-release hydromorphone with

immediate-release hydromorphone in patients with cancer pain. Canadian Palliative

Care Clinical Trials Group. Journal of Clinical Oncology, 1996. 14(5): p. 1713-7.

290. Hays, H., et al., Comparative clinical efficacy and safety of immediate release and

controlled release hydromorphone for chronic severe cancer pain. Cancer, 1994. 74(6): p. 1808-16.

291. Reddy, A., et al., The Conversion Ratio From Intravenous Hydromorphone to Oral

Opioids in Cancer Patients. J Pain Symptom Manage, 2017. 54(3): p. 280-288.

292. Bosilkovska, M., et al., Analgesics in patients with hepatic impairment:

pharmacology and clinical implications. Drugs, 2012. 72(12): p. 1645-69.

293. Masso Gonzalez, E.L., et al., Variability among nonsteroidal antiinflammatory drugs

in risk of upper gastrointestinal bleeding. Arthritis and Rheumatism, 2010. 62(6): p.

1592-601.

294. Michels, S.L., et al., Over-the-counter ibuprofen and risk of gastrointestinal bleeding

complications: a systematic literature review. Current Medical Research Opinion, 2012. 28(1): p. 89-99.

295. Volans, G., J. Monaghan, and M. Colbridge, Ibuprofen overdose. International

Journal of Clinical Practice Supplement, 2003(135): p. 54-60.

296. Krenova M and Pelclova D, Fatal poisoning with ibuprofen. Clinical Toxicology,

2005. 43: p. 537.

297. Wood DM, etc, and etc, Fatality after deliberate ingestion of sustained-release

ibuprofen: a case report. Critical Care, 2006. 10: p. R44.

298. Holubek, W., et al., A report of two deaths from massive ibuprofen ingestion.

Journal of Medical Toxicology, 2007. 3(2): p. 52-5.

299. Lodise, M., et al., Acute Ibuprofen intoxication: report on a case and review of the literature. American Journal of Forensic Medicine and Pathology, 2012. 33(3): p. 242-6.

300. Rainsford, K.D., Ibuprofen: pharmacology, efficacy and safety.

Inflammopharmacology, 2009. 17(6): p. 275-342.

301. Cheng HF and Harris RC, Cyclooxygenases, the kidney, and hypertension.

Hypertension, 2004. 43(3): p. 525-30.



Seite 17 von 39

302. Gengo, F.M., et al., Effects of ibuprofen on the magnitude and duration of aspirin's

inhibition of platelet aggregation: clinical consequences in stroke prophylaxis. Journal of

Clinical Pharmacology, 2008. 48(1): p. 117-22. 303. Awa, K., et al., Prediction of time-dependent interaction of aspirin with ibuprofen

using a pharmacokinetic/pharmacodynamic model. Journal of Clinical Pharmacy and

Therapeutics, 2012. 37(4): p. 469-74.

304. Persson, J., et al., The analgesic effect of racemic ketamine in patients with chronic

ischemic pain due to lower extremity arteriosclerosis obliterans. Acta Anaesthesiologica

Scandinavica, 1998. 42: p. 750–758.

305. Iacobucci, G.J., et al., Ketamine: An Update on Cellular and Subcellular Mechanisms

with Implications for Clinical Practice. Pain Physician, 2017. 20(2): p. E285-e301.

306. Mion, G. and T. Villevieille, Ketamine pharmacology: an update (pharmacodynamics

and molecular aspects, recent findings). CNS Neurosci Ther, 2013. 19(6): p. 370-80. 307. Luczak, J., A.H. Dickenson, and A. Kotlinska-Lemieszek, The role of ketamine, an

NMDA receptor antagonist, in the management of pain. Progress in Palliative Care,

1995. 3: p. 127–134.

308. Kotlinska-Lemieszek, A. and J. Luczak, Subanesthetic ketamine: an essential

adjuvant for intractable cancer pain. Journal Pain Symptom Management, 2004. 28(2):

p. 100–2.

309. Batchelor, G., Ketamine in neuropathic pain. The Pain Society Newsletter, 1999. 1:

p. 19.

310. Beltrutti, D., A. Trompeo, and S. DiSanto, The epidural and intrathecal administration of ketamine. Current Review of Pain, 1999. 3: p. 458–472.

311. Carr, D.B., et al., Safety and efficacy of intranasal ketamine for the treatment of

breakthrough pain in patients with chronic pain: a randomized, double-blind, placebo-

controlled, crossover study. Pain, 2004. 108(1-2): p. 17–27.

312. Haines, D. and S. Gaines, N of 1 randomised controlled trials of oral ketamine in

patients with chronic pain. Pain, 1999. 83: p. 283–287.

313. Lin, T., et al., Long-term epidural ketamine, morphine and bupivacaine attenuate

reflex sympathetic dystrophy neuralgia. Canadian Journal of Anaesthesia, 1998. 45: p.

175–177.

314. Mercadante, S., et al., Alternative treatments of breakthrough pain in patients receiving spinal analgesics for cancer pain. Journal of Pain and Symptom Management,

2005. 30(5): p. 485–91.

315. Mercadante, S., et al., Analgesic effect of intravenous ketamine in cancer patients

on morphine therapy: a randomized , controlled, double-blind, crossover, double-dose

study. Journal of Pain and Symptom Management, 2000. 20: p. 246–252.

316. Yeaman, F., et al., Sub-dissociative dose intranasal ketamine for limb injury pain in

children in the emergency department: a pilot study. Emerg Med Australas, 2013. 25(2):

p. 161-7.

317. Vranken, J.H., et al., Neuropathological findings after continuous intrathecal

administration of S(+)-ketamine for the management of neuropathic cancer pain. Pain, 2005. 117(1-2): p. 231–5.

318. Berger, J., et al., Ketamine-fentanyl-midazolam infusion for the control of

symptoms in terminal life care. American Journal of Hospice and Palliative Care, 2000.

17 (2)(2): p. 127–132.



Seite 18 von 39

319. Enck, R., A ketamine, fentanyl, and midazolam infusion for uncontrolled terminal

pain and agitation. American Journal of Hospice and Palliative Care, 2000. 17 (2)(2): p.

76–77. 320. Conway, M., et al., Use of continuous intravenous ketamine for end-stage cancer

pain in children. Journal of Pediatric Oncology Nursing, 2009. 26(2): p. 100-6.

321. White, P.F., et al., Pharmacology of ketamine isomers in surgical patients.

Anesthesiology, 1980. 52(3): p. 231–9.

322. Oye, I., et-al, and e. al, The chiral forms of ketamine as probes for NMDA receptor

function in humans., in NMDA receptor Related Agents: biochemistry, pharmacology

and behavior., T. Kameyama, Editor. 1991, NPP: Ann Arbor, Michigan. p. 381–389.

323. Mathisen, L., et al., Effect of ketamine, an NMDA receptor inhibitor, in acute and

chronic orofacial pain. Pain, 1995. 61: p. 215–220.

324. Pfenninger, E.G., M.E. Durieux, and S. Himmelseher, Cognitive impairment after small-dose ketamine isomers in comparison to equianalgesic racemic ketamine in

human volunteers. Anesthesiology, 2002. 96(2): p. 357–66.

325. Sener, S., et al., Ketamine with and without midazolam for emergency department

sedation in adults: a randomized controlled trial. Ann Emerg Med, 2011. 57(2): p. 109-

114 e2.

326. Hughes, A., et al., Ketamine. CME Bulletin Palliative Medicine, 1999. 1: p. 53.

327. Giannini, A., N. Underwood, and M. Condon, Acute ketamine intoxication treated

by haloperidol: a preliminary study. American Journal of Therapeutics, 2000. 7: p. 389–

391. 328. Subramaniam, K., B. Subramaniam, and R.A. Steinbrook, Ketamine as adjuvant

analgesic to opioids: a quantitative and qualitative systematic review. Anesthesia and

Analgesia, 2004. 99(2): p. 482–95, table of contents.

329. Bell RF, Perioperative ketamine for acute postoperative pain. Cochrane Database of

Systematic Reviews 2006, 2009. 1 (Updated 2009)

330. Jackson, K., et al., The effectiveness and adverse effects profile of "burst" ketamine

in refractory cancer pain: The VCOG PM 1-00 study. J Palliat Care, 2010. 26(3): p. 176-83.

331. Jackson, K., et al., "Burst" ketamine for refractory cancer pain: an open-label audit

of 39 patients. J Pain Symptom Manage, 2001. 22(4): p. 834-42. 332. Lee, E.N. and J.H. Lee, The Effects of Low-Dose Ketamine on Acute Pain in an

Emergency Setting: A Systematic Review and Meta-Analysis. PLoS One, 2016. 11(10): p.

e0165461.

333. White, M.C., et al., Pain management in 100 episodes of severe mucositis in

children. Pediatric Anesthesia, 2011. 21(4): p. 411-416.

334. Arroyo-Novoa, C.M., et al., Efficacy of small doses of ketamine with morphine to

decrease procedural pain responses during open wound care. Clin J Pain, 2011. 27(7): p.

561-6.

335. Kundra, P., et al., Oral ketamine and dexmedetomidine in adults' burns wound

dressing--A randomized double blind cross over study. Burns, 2013. 39(6): p. 1150-6. 336. Norambuena, C., et al., Oral ketamine and midazolam for pediatric burn patients: a

prospective, randomized, double-blind study. J Pediatr Surg, 2013. 48(3): p. 629-34.

337. Cevik, E., et al., Comparison of ketamine-low-dose midozolam with midazolam-

fentanyl for orthopedic emergencies: a double-blind randomized trial. Am J Emerg Med,

2013. 31(1): p. 108-13.



Seite 19 von 39

338. Finch, P.M., L. Knudsen, and P.D. Drummond, Reduction of allodynia in patients

with complex regional pain syndrome: A double-blind placebo-controlled trial of topical

ketamine. PAIN, 2009. 146(1–2): p. 18-25. 339. Gammaitoni, A., R.M. Gallagher, and M. Welz-Bosna, Topical ketamine gel: possible

role in treating neuropathic pain. Pain Medicine, 2000. 1(1): p. 97-100.

340. Slatkin, N.E. and M. Rhiner, Topical ketamine in the treatment of mucositis pain.

Pain Medicine, 2003. 4(3): p. 298-303.

341. Shillingburg, A., et al., Treatment of severe mucositis pain with oral ketamine

mouthwash. Support Care Cancer, 2017. 25(7): p. 2215-2219.

342. Bobo, W.V., et al., KETAMINE FOR TREATMENT-RESISTANT UNIPOLAR AND BIPOLAR

MAJOR DEPRESSION: CRITICAL REVIEW AND IMPLICATIONS FOR CLINICAL PRACTICE.

Depress Anxiety, 2016. 33(8): p. 698-710.

343. Bartoli, F., et al., Ketamine as a rapid-acting agent for suicidal ideation: A meta-analysis. Neurosci Biobehav Rev, 2017. 77: p. 232-236.

344. Caddy, C., et al., Ketamine and other glutamate receptor modulators for depression

in adults. Cochrane Database Syst Rev, 2015(9): p. CD011612.

345. Chong, C.C., et al., Bioavailability of Ketamine After Oral or Sublingual

Administration. Pain Medicine, 2006. 7: p. 469–469.

346. Yanagihara, Y., et al., Plasma concentration profiles of ketamine and norketamine

after administration of various ketamine preparations to healthy Japanese volunteers.

Biopharmacentrics and Drug Disposition, 2003. 24(1): p. 37-43.

347. Grant, I.S., W.S. Nimmo, and J.A. Clements, Pharmacokinetics and analgesic effects of IM and oral ketamine. British Journal of Anaesthesia, 1981. 53: p. 805–810.

348. Domino, E., et al., Ketamine kinetics in unmedicated and diazepam premedicated

subjects. Clinical Pharmacology and Therapeutics, 1984. 36: p. 645–653.

349. Rabben, T., P. Skjelbred, and I. Oye, Prolonged analgesic effect of ketamine, an N-

methyl-D-aspartate receptor inhibitor, in patients with chronic pain. Journal of

Pharmacology and Experimental Therapeutics, 1999. 289: p. 1060–1066.

350. Ward, J. and C. Standage, Angina pain precipitated by a continuous subcutaneous

infusion of ketamine. Journal of Pain and Symptom Management, 2003. 25(1): p. 6–7.

351. Hagelberg N, etc, and etc, Clarythromycin, a potent inhibitor of CYP3A, greatly

increases exposure to oral S-ketamine. European Journal of Pain, 2010. 14: p. 625-629. 352. Peltoniemi, M.A., et al., S-ketamine concentrations are greatly increased by

grapefruit juice. European Journal of Clinical Pharmacology, 2012. 68(6): p. 979-86.

353. Peltoniemi, M.A., et al., Rifampicin has a profound effect on the pharmacokinetics

of oral S-Ketamine and less on intravenous S-ketamine. Basic and Clinical Pharmacology

and Toxicology, 2012. 111(5): p. 325-32.

354. Peltoniemi, M.A., et al., St John's wort greatly decreases the plasma concentrations

of oral S-ketamine. Fundam Clin Pharmacol, 2012. 26(6): p. 743-50.

355. Winstock, A.R., et al., The prevalence and natural history of urinary symptoms

among recreational ketamine users. BJU Int, 2012. 110(11): p. 1762-6.

356. Chu, P.S., et al., The destruction of the lower urinary tract by ketamine abuse: a new syndrome? BJU Int, 2008. 102(11): p. 1616-22.

357. Shahani, R., et al., Ketamine-associated ulcerative cystitis: a new clinical entity.

Urology, 2007. 69(5): p. 810-2.

358. Jhang, J.F., Y.H. Hsu, and H.C. Kuo, Possible pathophysiology of ketamine-related

cystitis and associated treatment strategies. Int J Urol, 2015. 22(9): p. 816-25.



Seite 20 von 39

359. Dundee, J.W., et al., Changes in serum enzyme levels following ketamine infusions.

Anaesthesia, 1980. 35(1): p. 12-6.

360. Wong, S.W., et al., Dilated common bile ducts mimicking choledochal cysts in ketamine abusers. Hong Kong Med J, 2009. 15(1): p. 53-6.

361. Ng, S.H., et al., Emergency department presentation of ketamine abusers in Hong

Kong: a review of 233 cases. Hong Kong Med J, 2010. 16(1): p. 6-11.

362. Noppers, I.M., et al., Drug-induced liver injury following a repeated course of

ketamine treatment for chronic pain in CRPS type 1 patients: a report of 3 cases. Pain,

2011. 152(9): p. 2173-8.

363. Seto, W.K., et al., Ketamine-induced cholangiopathy: a case report. Am J

Gastroenterol, 2011. 106(5): p. 1004-5.

364. Ng, S.H., et al., Dilated common bile ducts in ketamine abusers. Hong Kong Med J,

2009. 15(2): p. 157; author reply 157. 365. Lee, S.T., et al., Apoptotic insults to human HepG2 cells induced by S-(+)-ketamine

occurs through activation of a Bax-mitochondria-caspase protease pathway. Br J

Anaesth, 2009. 102(1): p. 80-9.

366. Fallon, M., Personal communication. . 2015.

367. Mitchell, A.C., Generalized hyperalgesia and allodynia following abrupt cessation of

subcutaneous ketamine infusion. Palliative Medicine, 1999. 13(5): p. 427–8.

368. Benitez-Rosario MA, etc, and etc, A strategy for conversion from subcutaneous to

oral ketamine in cancer pain patients: efficacy of a 1:1 ratio. Journal of Pain and

Symptom Management, 2011. 10: p. 1098-1105. 369. Benitez-Rosario, M., et al., A retrospective comparison of the dose ratio between

subcutaneous and oral ketamine. Journal of Pain and Symptom Management, 2003.

25(5): p. 400–2.

370. Fitzgibbon, E.J., et al., Low dose ketamine as an analgesic adjuvant in difficult pain

syndromes: a strategy for conversion from parenteral to oral ketamine. J Pain Symptom

Manage, 2002. 23(2): p. 165–70.

371. Broadley, K., A. Kurowska, and A. Tookman, Ketamine injection used orally.


372. Clark, J.L. and G.E. Kalan, Effective treatment of severe cancer pain of the head

using low-dose ketamine in an opioid-tolerant patient. Journal of Pain and Symptom Management, 1995. 10: p. 310–314.

373. Vielvoye-Kerkmeer, A., Clinical experience with ketamine. Journal of Pain and

Symptom Management, 2000. 19: p. 3.

374. Oshima, E., et al., Continuous subcutaneous injection of ketamine for cancer pain.

Canadian Journal of Anaesthetics, 1990. 37: p. 385–392.

375. Lloyd-Williams, M., Ketamine for cancer pain. Journal of Pain and Symptom

Management, 2000. 19: p. 79–80.

376. Cherry, D.A., et al., Ketamine as an adjunct to morphine in the treatment of pain.

Pain, 1995. 62: p. 119–121.

377. Bell, R., Low-dose subcutaneous ketamine infusion and morphine tolerance. Pain, 1999. 83: p. 101–103.

378. Mason, K.P., et al., Evolution of a protocol for ketamine-induced sedation as an

alternative to general anesthesia for interventional radiologic procedures in pediatric

patients. Radiology, 2002. 225(2): p. 457–65.



Seite 21 von 39

379. Okamoto, Y., et al., Can gradual dose titration of ketamine for management of

neuropathic pain prevent psychotomimetic effects in patients with advanced cancer?

Am J Hosp Palliat Care, 2013. 30(5): p. 450-4. 380. Hocking G, etc, and etc, Ketamine: does life begin at 40? Pain Clinical Updates. IASP,

2007. XV. Issue 3.

381. Fallon M, Personal communication. 2010.

382. Hardy, J., et al., A prospective survey of the use of dexamethasone on a palliative

care unit. Palliative Medicine, 2001. 15: p. 3–8.

383. NICE. Metastatic spinal cord compression. Clinical guideline CG75. 2014; Available

from: www.nice.org.uk/CG75.

384. Rowell, N.P. and F.V. Gleeson, Steroids, radiotherapy, chemotherapy and stents for

superior vena caval obstruction in carcinoma of the bronchus. Clinical Oncology, 2002.

14(5): p. 338-351. 385. Elsayem, A. and E. Bruera, High-dose corticosteroids for the management of

dyspnea in patients with tumor obstruction of the upper airway. Supportive Care in

Cancer, 2007. 15(12): p. 1437-9.

386. Feuer, D.J. and K.E. Broadley, Corticosteroids for the resolution of malignant bowel

obstruction in advanced gynaecological and gastrointestinal cancer 2000 (2). Update

2009. Cochrane Database of Systematic Reviews, 2009: p. CD001219.

387. Laval, G., et al., The use of steroids in the management of inoperable intestinal

obstruction in terminal cancer patients: do they remove the obstruction? Palliative

Medicine, 2000. 14: p. 3–10. 388. Ndibe, C., C.G. Wang, and G. Sonpavde, Corticosteroids in the management of

prostate cancer: a critical review. Curr Treat Options Oncol, 2015. 16(2): p. 6.

389. Haywood, A., et al., Corticosteroids for the management of cancer-related pain in

adults. Cochrane Database Syst Rev, 2015(4): p. Cd010756.

390. Paulsen, O., et al., Efficacy of methylprednisolone on pain, fatigue, and appetite loss

in patients with advanced cancer using opioids: a randomized, placebo-controlled,

double-blind trial. J Clin Oncol, 2014. 32(29): p. 3221-8.

391. Rhen, T. and J.A. Cidlowski, Antiinflammatory action of glucocorticoids--new

mechanisms for old drugs. N Engl J Med, 2005. 353(16): p. 1711–23.

392. Swartz, S. and R. Dluhy, Corticosteroids: clinical pharmacology and therapeutic use. Drugs, 1978. 16: p. 238–255.

393. Demoly, P. and K. Chung, Pharmacology of corticosteroids. Respiratory Medicine,

1998. 92: p. 385–394.

394. Narum, S., T. Westergren, and M. Klemp, Corticosteroids and risk of gastrointestinal

bleeding: a systematic review and meta-analysis. BMJ Open, 2014. 4(5): p. e004587.

395. Ellershaw, J. and M. Kelly, Corticosteroids and peptic ulceration. Palliative Medicine,

1994. 8: p. 313-9.

396. Naesdal, J. and K. Brown, NSAID-associated adverse effects and acid control aids to

prevent them: a review of current treatment options. Drug Safety, 2006. 29(2): p. 119-

32. 397. Fardet, L., et al., Corticosteroid-induced adverse events in adults: frequency,

screening and prevention. Drug Safety, 2007. 30(10): p. 861-81.

398. Yamaguchi, T., et al., Pneumocystis pneumonia in patients treated with long-term

steroid therapy for symptom palliation: a neglected infection in palliative care. Am J

Hosp Palliat Care, 2014. 31(8): p. 857-61.



Seite 22 von 39

399. BNF, Section 6 Corticosteroids, in British National Formulary 2017, British Medical

Association and the Royal Pharmaceutical Society of Great Britain: London.

400. Jick, S., C. Vasilakis-Scaramozza, and W. Maier, The risk of cataract among users of inhaled steroids. Epidemiology, 2001. 12: p. 229–234.

401. Piper, J.M., et al., Corticosteroid use and peptic ulcer disease: role of nonsteroidal

anti-inflammatory drugs. Annals of Internal Medicine, 1991. 114: p. 735–740.

402. Rousseau, P., Sudden withdrawal of corticosteroids: a commentary. American

Journal of Hospice and Palliative Care, 2004. 21(3): p. 169–71.

403. Navari, R.M. and M. Aapro, Antiemetic Prophylaxis for Chemotherapy-Induced

Nausea and Vomiting. N Engl J Med, 2016. 374(14): p. 1356-67.

404. Gralla, R., et al., Recommendations for the use of antiemetics: evidence-based,

clinical practice guidelines. Journal of Clinical Oncology, 1999. 17: p. 2971–2994.

405. Editorial, Ondansetron versus dexamethasone for chemotherapy-induced emesis. Lancet, 1991. 338: p. 478.

406. Willox, J.C., et al., Prednisolone as an appetite stimulant in patients with cancer.

British Medical Journal, 1984. 288: p. 27.

407. DGN, ed. S2k-Leitlnie 030/060: Hirnmetastasern und Meningeosis neoplastica. ed.

AWMF. 2014, AWMF.

408. Kirkham, S., The palliation of cerebral tumours with high-dose dexamethasone: a

review. Palliative Medicine, 1988. 2: p. 27–33.

409. Vecht, C., et al., Initial bolus of conventional versus high-dose dexamethasone in

metastatic spinal cord compression. Neurology, 1989. 39: p. 1255–1257. 410. Schumann, C., Medical, nutritional and technological properties of lactulose. An

update. European Journal of Nutrition, 2002. 41 Suppl 1: p. I17–25.

411. Zeng, Z., et al., Influence of lactulose on the cognitive level and quality of life in

patients with minimal hepatic encephalopathy. Chinese Journal of Clinical Rehabilitation,

2006. 10(22): p. 165–167.

412. Lynch, B.A., The synaptic vesicle protein SV2A is the binding site for the

antiepileptic drug levetiracetam. Proceedings of the National Academy of Sciences of

the United States of America, 2004. 101 (26): p. 9861-9866.

413. Klitgaard, H., et al., Brivaracetam: Rationale for discovery and preclinical profile of a

selective SV2A ligand for epilepsy treatment. Epilepsia, 2016. 57(4): p. 538-48. 414. Dinkelacker, V., et al., Aggressive behavior of epilepsy patients in the course of

levetiracetam add-on therapy: report of 33 mild to severe cases. Epilepsy Behaviour,

2003. 4(5): p. 537-47.

415. Cramer, J.A., et al., A systematic review of the behavioral effects of levetiracetam in

adults with epilepsy, cognitive disorders, or an anxiety disorder during clinical trials.

Epilepsy Behaviour, 2003. 4(2): p. 124-32.

416. Lopez-Saca, J.M., et al., Repeated Use of Subcutaneous Levetiracetam in a Palliative

Care Patient. Journal of Pain and Symptom Management, 2013.

417. Bagli, M., et al., Bioequivalence and absolute bioavailability of oblong and coated

levomepromazine tablets in CYP2D6 phenotyped subjects. International Journal of Clinical Pharmacology and Therapeutics, 1995. 33(12): p. 646-52.

418. Dahl, S.G., R.E. Strandjord, and S. Sigfusson, Pharmacokinetics and relative

bioavailability of levomepromazine after repeated administration of tablets and syrup.

European Journal of Clinical Pharmacology, 1977. 11(4): p. 305-10.

419. Morley, J. and M. Makin, The use of methadone in cancer pain poorly responsive to

other opioids. Pain Reviews, 1998. 5: p. 51–58.



Seite 23 von 39

420. Gannon, C., The use of methadone in the care of the dying. European Journal of

Palliative Care, 1997. 4(5): p. 152–158.

421. Watanabe, S., Methadone the renaissance. Journal of Palliative Care, 2001. 17 (2)(2): p. 117–120.

422. Davis, M.P. and D. Walsh, Methadone for relief of cancer pain: a review of

pharmacokinetics, pharmacodynamics, drug interactions and protocols of

administration. Supportive Care in Cancer, 2001. 9(2): p. 73–83.

423. Raynor, K., et al., Pharmacological characterization of the cloned kappa-, delta-, and

mu-opioid receptors. Molecular Pharmacology, 1994. 45(2): p. 330–334.

424. Ebert, B., S. Anderson, and P. Krogsgaard-Larsen, Ketobemidone, methadone and

pethidine are non-competitive N-methyl-D-aspartate (NMDA) antagonists in the rat

cortex and spinal cord. Neuroscience Letter, 1995. 187: p. 165–168.

425. Gorman, A., K. Elliott, and C. Inturrisi, The d- and l- isomers of methadone bind to the non-competitive site on the N-methyl-D-aspartate (NMDA) receptor in rat forebrain

and spinal cord. Neuroscience Letters, 1997. 223: p. 5–8.

426. Matsui, A. and J.T. Williams, Activation of micro-opioid receptors and block of Kir3

potassium channels and NMDA receptor conductance by L- and D-methadone in rat

locus coeruleus. Br J Pharmacol, 2010. 161(6): p. 1403-13.

427. Codd, E., et al., Serotonin and norepinephrine uptake inhibiting activity of centrally

acting analgesics: structural determinants and role in antinociception. Journal of

Pharmacology and Experimental Therapeutics, 1995. 274: p. 1263–1270.

428. Ferrari, A., et al., Methadone-metabolism, pharmacokinetics and interactions. Pharmacological Research, 2004. 50(6): p. 551-9.

429. Robinson, A.E. and F.M. Williams, The distribution of methadone in man. Journal of

Pharmacy and Pharmacology, 1971. 23: p. 353–358.

430. Eap, C.B., C. Cuendet, and P. Baumann, Binding of D-methadone, L-methadone and

DL-methadone to proteins in plasma of healthy volunteers: role of variants of X1-acid

glycoprotein. Clinical Pharmacology and Therapeutics, 1990. 47: p. 338–346.

431. Chatham, M.S., et al., Dose ratios between high dose oral morphine or equivalents

and oral methadone. J Palliat Med, 2013. 16(8): p. 947-50.

432. Benitez-Rosario, M.A., et al., Morphine-methadone opioid rotation in cancer

patients: analysis of dose ratio predicting factors. Journal of Pain and Symptom Management, 2009. 37(6): p. 1061-8.

433. Weschules, D.J. and K.T. Bain, A systematic review of opioid conversion ratios used

with methadone for the treatment of pain. Pain Medicine, 2008. 9(5): p. 595-612.

434. Cornish, C.J. and J.C. Keen, An alternative low-dose ad libitum schedule for

conversion of other opioids to methadone. Palliative Medicine, 2003. 17(7): p. 643–4.

435. Walker, P.W., et al., Switching from methadone to a different opioid: what is the

equianalgesic dose ratio? J Palliat Med, 2008. 11(8): p. 1103-8.

436. Furlan, V., et al., Methadone is poorly removed by haemodialysis. Nephrology,

Dialysis, Transplantation, 1999. 14(1): p. 254–5.

437. Fisher, K., C. Stiles, and N.A. Hagen, Characterization of the early pharmacodynamic profile of oral methadone for cancer-related breakthrough pain: a pilot study. Journal of

Pain and Symptom Management, 2004. 28(6): p. 619–25.

438. Hagen, N.A., et al., A formal feasibility study of sublingual methadone for

breakthrough cancer pain. Palliative Medicine, 2010. 24(7): p. 696-706.

439. Lugo, R.A., et al., Pharmacokinetics of methadone. Journal of Pain and Palliative

Care Pharmacotherapy, 2005. 19(4): p. 13-24.



Seite 24 von 39

440. Nilsson, M.I., et al., Pharmacokinetics of methadone during maintenance

treatment: adaptive changes during the induction phase. European Journal of Clinical

Pharmarcology, 1982. 22: p. 343–349. 441. Hendra, T., S. Gerrish, and A. Forrest, Fatal methadone overdose. British Medical

Journal, 1996. 313: p. 481–482.

442. Wilcock, A. and J.M. Beattie, Prolonged QT interval and methadone: implications

for palliative care. Current Opinion in Supportive and Palliative Care, 2009. 3: p. 252-257.

443. Ansermot, N., et al., Substitution of (R,S)-methadone by (R)-methadone: Impact on

QTc interval. Arch Intern Med, 2010. 170(6): p. 529-36.

444. Kreek, M.J., et al., Rifampin-induced methadone withdrawal. New England Journal

of Medicine, 1976. 294: p. 1104–1106.

445. Wahawisan, J., et al., Methadone toxicity due to smoking cessation--a case report

on the drug-drug interaction involving cytochrome P450 isoenzyme 1A2. Ann Pharmacother, 2011. 45(6): p. e34.

446. Sarhill, N., et al., Methadone-induced myoclonus in advanced cancer. American

Journal of Hospice and Palliative Care, 2001. 18 (1): p. 51–53.

447. Davis, M.P., L.A. Shaiova, and M.S. Angst, When opioids cause pain. Journal of

Clinical Oncology, 2007. 25(28): p. 4497–8.

448. El Osta, B., et al., Intractable pain: intoxication or undermedication? Journal of

Palliative Medicine, 2007. 10(3): p. 811–4.

449. Bruera, E., et al., Local toxicity with subcutaneous methadone. Experience of two

centers. Pain, 1991. 45: p. 141–143. 450. Maingi, S., N. Moryl, and F. Andrew, (244) Symptomatic hypoglycemia due to

escalating doses of intravenous methadone. The Journal of Pain. 9(4): p. 37.

451. Faskowitz, A.J., V.N. Kramskiy, and G.W. Pasternak, Methadone-induced

hypoglycemia. Cell Mol Neurobiol, 2013. 33(4): p. 537-42.

452. Saifan, C., et al., Methadone induced sensorineural hearing loss. Case Rep Med,

2013. 2013: p. 242730.

453. Vorasubin, N., A.P. Calzada, and A. Ishiyama, Methadone-induced bilateral severe

sensorineural hearing loss. Am J Otolaryngol, 2013. 34(6): p. 735-8.

454. Ripamonti, C., E. Zecca, and E. Bruera, An update on the clinical use of methadone

cancer pain. Pain, 1997. 70: p. 109–115. 455. Hagen, N. and E. Wasylenko, Methadone: outpatient titration and monitoring

strategies in cancer patients. Journal of Pain and Symptom Management, 1999. 18: p.

369–375.

456. Mercadante, S., A. Casuccio, and L. Calderone, Rapid switching from morphine to

methadone in cancer patients with poor response to morphine. Journal of Clinical

Oncology, 1999. 17: p. 3307–3312.

457. Scholes, C., N. Gonty, and I. Trotman, Methadone titration in opioid-resistant

cancer pain. European Journal of Cancer Care, 1999. 8: p. 26–29.

458. Mercadante, S., et al., Switching from morphine to methadone to improve

analgesia and tolerability in cancer patients: a prospective study. Journal of Clinical Oncology, 2001. 19(11): p. 2898–2904.

459. Nauck, F., C. Ostgathe, and E. Dickerson, A German model for methadone

conversion. American Journal of Hospice and Palliative Care, 2001. 18 (3): p. 200–202.

460. Tse, D.M., et al., An ad libitum schedule for conversion of morphine to methadone

in advanced cancer patients: an open uncontrolled prospective study in a Chinese

population. Palliative Medicine, 2003. 17(2): p. 206–11.



Seite 25 von 39

461. Soares, L.G., Methadone for cancer pain: what have we learned from clinical

studies? American Journal of Hospice and Palliative Care, 2005. 22(3): p. 223–227.

462. Lipman, A.G., Methadone: effective analgesia, confusion, and risk. Journal of Pain and Palliative Care Pharmacotherapy, 2005. 19 (2)(2): p. 3–5.

463. Twycross, R.G., A comparison of diamorphine with cocaine and methadone. British

Journal of Clinical Pharmacology 1977. 4: p. 691–692.

464. Auret, K., et al., Pharmacokinetics and pharmacodynamics of methadone

enantiomers in hospice patients with cancer pain. Ther Drug Monit, 2006. 28(3): p. 359-

66.

465. Blackburn, D., Methadone: the analgesic. European Journal of Palliative Care, 2005.

12: p. 188–191.

466. Blackburn, D., E. Somerville, and J. Squire, Methadone: an alternative conversion

regime. European Journal of Palliative Care, 2002. 9: p. 93–96. 467. Bruera, E., et al., Opioid rotation in patients with cancer pain. Cancer, 1996. 78: p.

852–857.

468. McLean, S. and F. Twomey, Methods of Rotation From Another Strong Opioid to

Methadone for the Management of Cancer Pain: A Systematic Review of the Available

Evidence. J Pain Symptom Manage, 2015. 50(2): p. 248-59.e1.

469. Moksnes, K., et al., How to switch from morphine or oxycodone to methadone in

cancer patients? a randomised clinical phase II trial. Eur J Cancer, 2011. 47(16): p. 2463-

70.

470. Moksnes, K., et al., Serum concentrations of opioids when comparing two switching strategies to methadone for cancer pain. Eur J Clin Pharmacol, 2012. 68(8): p. 1147-56.

471. Santiago-Palma, J., et al., Intravenous methadone in the management of chronic

cancer pain: safe and effective starting doses when substituting methadone for fentanyl.

Cancer, 2001. 92(7): p. 1919–25.

472. Zimmermann, C., et al., Rotation to methadone after opioid dose escalation: How

should individualization of dosing occur? Journal of Pain and Palliative Care

Pharmacotherapy, 2005. 19 (2)(2): p. 25–31.

473. Courtemanche, F., et al., Methadone as a Coanalgesic for Palliative Care Cancer

Patients. J Palliat Med, 2016. 19(9): p. 972-8.

474. Fallon, M.T. and B.J. Laird, A systematic review of combination step III opioid therapy in cancer pain: an EPCRC opioid guideline project. Palliat Med, 2011. 25(5): p.

597-603.

475. Mathew, P. and P. Storey, Subcutaneous methadone in terminally ill patients:

manageable local toxicity. Journal of Pain and Symptom Management, 1999. 18: p. 49–

52.

476. Centeno, C. and F. Vara, Intermittent subcutaneous methadone administration in

the management of cancer pain. Journal of Pain and Palliative Care Pharmacotherapy,

2005. 19(2): p. 7–12.

477. Fitzgibbon, D. and L. Ready, Intravenous high-dose methadone administered by

patient controlled analgesia and continuous infusion for the treatment of cancer pain refractory to high-dose morphine. Pain, 1997. 73: p. 259–261.

478. Manfredi, P.L. and R.W. Houde, Prescribing methadone, a unique analgesic. Journal

of Supportive Oncology, 2003. 1(3): p. 216–20.

479. Gallagher, R.E., et al., Analgesic effects of topical methadone: a report of four cases.

Clinical Journal of Pain, 2005. 21(2): p. 190-2.



Seite 26 von 39

480. Gallagher, R., Methadone mouthwash for the management of oral ulcer pain.

Journal of Pain and Symptom Management, 2004. 27(5): p. 390–1.

481. Slominski, R.M., et al., Melatonin membrane receptors in peripheral tissues: distribution and functions. Mol Cell Endocrinol, 2012. 351(2): p. 152-66.

482. Saper, C.B., The central circadian timing system. Curr Opin Neurobiol, 2013. 23(5):

p. 747-51.

483. Westermann, J., et al., System consolidation during sleep - a common principle

underlying psychological and immunological memory formation. Trends Neurosci, 2015.

38(10): p. 585-597.

484. Brown, S.A., Circadian Metabolism: From Mechanisms to Metabolomics and

Medicine. Trends Endocrinol Metab, 2016. 27(6): p. 415-426.

485. Rihel, J. and A.F. Schier, Sites of action of sleep and wake drugs: insights from model

organisms. Curr Opin Neurobiol, 2013. 23(5): p. 831-40. 486. Davis, M.P., et al., Insomnia in patients with advanced cancer. Am J Hosp Palliat

Care, 2014. 31(4): p. 365-73.

487. Induru, R.R. and D. Walsh, Cancer-related insomnia. Am J Hosp Palliat Care, 2014.

31(7): p. 777-85.

488. Renom-Guiteras, A., et al., Insomnia among patients with advanced disease during

admission in a Palliative Care Unit: a prospective observational study on its frequency

and association with psychological, physical and environmental factors. BMC Palliat

Care, 2014. 13: p. 40.

489. Yennurajalingam, S., et al., Association between Daytime Activity, Fatigue, Sleep, Anxiety, Depression, and Symptom Burden in Advanced Cancer Patients: A Preliminary

Report. J Palliat Med, 2016. 19(8): p. 849-56.

490. Benkert, O. and H. Hippius, Kompendium der Psychiatrischen Pharmakotherapie.

2017, Springer Berlin Heidelberg. p. 273

491. ratiopharm. Fachinformation Melperon-ratiopharm®. 2014 Juni 2014 23.12.2014];

Available from: http://www.fachinfo.de.

492. Hinz, B., et al., Dipyrone elicits substantial inhibition of peripheral cyclooxygenases

in humans: new insights into the pharmacology of an old analgesic. Faseb J, 2007.

21(10): p. 2343-51. 493. Nikolova, I., et al., Metamizole: A Review Profile of a Well-Known “Forgotten” Drug.

Part I: Pharmaceutical and Nonclinical Profile. Biotechnology & Biotechnological

Equipment, 2012. 26(6): p. 3329-3337.

494. AKDÄ, „Aus der UAW-Datenbank“ Agranulozytose nach Metamizol – sehr selten,

aber häufiger als gedacht. Deutsches Ärzteblatt, 2011. 108(33): p. A 1758-A1759.

495. Andrade, S.E., C. Martinez, and A.M. Walker, Comparative safety evaluation of non-

narcotic analgesics. Journal of Clinical Epidemiology, 1998. 51(12): p. 1357-1365.

496. Zylber-Katz, E., et al., Dipyrone metabolism in liver disease. Clinical Pharmacology

and Therapeutics, 1995. 58(2): p. 198-209.

497. Heinemeyer, G., et al., The kinetics of metamizol and its metabolites in critical-care patients with acute renal dysfunction. Eur J Clin Pharmacol, 1993. 45(5): p. 445-50.

498. Zapater, P., et al., Acute Effects of Dipyrone on Renal Function in Patients with

Cirrhosis: A Randomized Controlled Trial. Basic Clin Pharmacol Toxicol, 2014.

499. Edwards, J., et al., Single dose dipyrone for acute postoperative pain. Cochrane

database of systematic reviews (Online), 2010. 9.



Seite 27 von 39

500. Saussele, T., et al., Selective induction of human hepatic cytochromes P450 2B6 and

3A4 by metamizole. Clinical Pharmacology and Therapeutics, 2007. 82(3): p. 265-274.

501. deMattos, H., Relations between alcoholism and the gastrointestinal system. Experience using metronidazole. [In Portuguese]. Hospital (Rio J). 1968. 74: p. 1669–

1676.

502. Penick, S., R. Carrier, and J. Sheldon, Metronidazole in the treatment of alcoholism.

American Journal of Psychiatry, 1969. 125: p. 1063–1066.

503. Plosker, G., Possible interaction between ethanol and vaginally administered

metronidazole. Clinical Pharmacy, 1987. 6: p. 189–193.

504. Newman, V., M. Allwood, and R. Oakes, The use of metronidazole gel to control the

smell of malodorous lesions. Palliative Medicine, 1989. 3: p. 303–305.

505. Kalinski C, etc, and etc, Effectiveness of a topical formulation containing

metronidazole for wound odor and exudate control. Wounds, 2005. 17: p. 84-90. 506. Ashford, R., et al., Double-blind trial of metronidazole in malodorous ulcerating

tumours. Lancet, 1984. 1(8388): p. 1232–3.

507. Editorial, Management of smelly tumours. Lancet, 1990. 335: p. 141–142.

508. Thomas, S. and N. Hay, The antimicrobial properties of two metronidazole

medicated dressings used to treat malodorous wounds. Pharmaceutical Journal, 1991.

246: p. 264–266.

509. George, R., et al., Improving malodour management in advanced cancer: a 10-year

retrospective study of topical, oral and maintenance metronidazole. BMJ Support Palliat

Care, 2017. 7(3): p. 286-291. 510. Stahl, S.M., Essential Psychopharmacology. Neuroscientific basis and practical

applications 3ed. 2008, Cambridge: Cambridge University Press.

511. Devoto, P., et al., Mirtazapine-induced corelease of dopamine and noradrenaline

from noradrenergic neurons in the medial prefrontal and occipital cortex. European

Journal of Pharmacology, 2004. 487(1-3): p. 105-11.

512. Croom, K.F., C.M. Perry, and G.L. Plosker, Mirtazapine: a review of its use in major

depression and other psychiatric disorders. CNS Drugs, 2009. 23(5): p. 427-52.

513. Kim, S.W., et al., Effectiveness of mirtazapine for nausea and insomnia in cancer

patients with depression. Psychiatry and Clinical Neurosciences, 2008. 62(1): p. 75-83.

514. Chen, C.C., et al., Premedication with mirtazapine reduces preoperative anxiety and postoperative nausea and vomiting. Anesthesia and Analgesia, 2008. 106(1): p. 109-13,

table of contents.

515. Abed, R. and M. Cooper, Mirtazapine causing hyperphagia. British Journal of

Psychiatry, 1999. 174(2): p. 181–182.

516. Brannon, G. and K. Stone, The use of mirtazapine in a patient with chronic pain.

Journal of Pain and Symptom Management, 1999. 18: p. 382–385.

517. Krajnik, M. and Z. Zylicz, Understanding pruritus in systemic disease. Journal of Pain

and Symptom Management, 2001. 21(2): p. 151–168.

518. Smith, H.S., Peripherally-acting opioids. Pain Physician, 2008. 11(2 Suppl): p. S121–

32. 519. McQuay, H.J., et al., Oral morphine in cancer pain: influences on morphine and

metabolite concentration. Clinical Pharmacology and Therapeutics, 1990. 48: p. 236–

244.

520. Osborne, R.J., S.P. Joel, and M.L. Slevin, Morphine intoxication in renal failure: the

role of morphine-6-glucuronide. British Medical Journal, 1986. 292: p. 1548–1549.



Seite 28 von 39

521. Thompson, P., et al., Mophine-6-glucuronide: a metabolite of morphine with

greater emetic potency than morphine in the ferret. British Journal of Pharmacology,

1992. 106: p. 3–8. 522. Klimas, R. and G. Mikus, Morphine-6-glucuronide is responsible for the analgesic

effect after morphine administration: a quantitative review of morphine, morphine-6-

glucuronide, and morphine-3-glucuronide. Br J Anaesth, 2014. 113(6): p. 935-44.

523. Franken, L.G., et al., Pharmacokinetics of Morphine, Morphine-3-Glucuronide and

Morphine-6-Glucuronide in Terminally Ill Adult Patients. Clin Pharmacokinet, 2016.

55(6): p. 697-709.

524. Gretton S and Riley J, Morphine metabolites: a review of their clinical effects.

European Journal of Palliative Care, 2008. 15: p. 110-114.

525. Hanks, G., et al., Morphine and alternative opioids in cancer pain: the EAPC

recommendations. British Journal of Cancer, 2001. 84(5): p. 587–593. 526. Takahashi, M., et al., The oral-to-intravenous equianalgesic ratio of morphine based

on plasma concentrations of morphine and metabolites in advanced cancer patients

receiving chronic morphine treatment. Palliat Med, 2003. 17(8): p. 673-8.

527. Ripamonti, C. and E. Bruera, Rectal, buccal and sublingual narcotics for the

management of cancer pain. Journal of Palliative Care, 1991. 7 (1)(1): p. 30–35.

528. Krajnik, M., I. Finlay, and Z. Zylicz, Opioids affect inflammation and the immune

system. Pain Reviews, 1998. 5: p. 147–154.

529. Krajnik, M. and Z. Zylicz, Topical opioids - fact or fiction? Progress in Palliative Care, 1997. 5: p. 101–106.

530. Ribeiro, M.D., S.P. Joel, and G. Zeppetella, The bioavailability of morphine applied

topically to cutaneous ulcers. Journal of Pain and Symptom Management, 2004. 27(5): p.

434–9.

531. Rémi, C. and A. Thalmeier, Herstellung von Morphin-Gel. Krankenhauspharmazie,

2010. 31(12): p. 543-544.

532. Herbig, S., Herstellung von Morphin-Gel 0,1 %. Krankenhauspharmazie, 2011. 32(6):

p. 367.

533. Zeppetella, G. and M.D. Ribeiro, Morphine in intrasite gel applied topically to

painful ulcers. Journal of Pain and Symptom Management, 2005. 29(2): p. 118–119. 534. Krajnik, M., et al., Potential uses of topical opioids in palliative care - report of 6

cases. Pain, 1999. 80: p. 121–125.

535. Cerchietti, L.C., et al., Effect of topical morphine for mucositis-associated pain

following concomitant chemoradiotherapy for head and neck carcinoma. Cancer, 2002.

95(10): p. 2230–6.

536. Vayne-Bossert, P., et al., Effect of topical morphine (mouthwash) on oral pain due

to chemotherapy- and/or radiotherapy-induced mucositis: a randomized double-blinded

study. Journal of Palliative Medicine, 2010. 13(2): p. 125-8.

537. Cerchietti, L.C., et al., Potential utility of the peripheral analgesic properties of

morphine in stomatitis-related pain: a pilot study. Pain, 2003. 105(1-2): p. 265-73. 538. BNF, Emergency treatment of poisoning, in British National Formulary (No. 60).

2014, British Medical Association and Royal Pharmaceutical Society of Great Britain:

London. Current BNF available from: www.bnf.org/bnf/bnf/current/.

539. Gurusamy, K.S., et al., Somatostatin analogues for pancreatic surgery. Cochrane

Database of Systematic Reviews, 2012. 6: p. CD008370.



Seite 29 von 39

540. Spinell, C., et al., Postoperative salivary fistula: therapeutic action of octreotide.

Surgery, 1995. 117(1): p. 117–8.

541. Coughlin, S., et al., Somatostatin analogues for the treatment of enterocutaneous fistulas: a systematic review and meta-analysis. World Journal of Surgery, 2012. 36(5): p.

1016-29.

542. Lam, C. and S. Wong, Use of somatostatin analog in the management of traumatic

parotid fistula. Surgery, 1996. 119: p. 481–482.

543. Dorta, G., Role of octreotide and somatostatin in the treatment of intestinal

fistulae. Digestion, 1999. 60 (suppl 2): p. 53–6.

544. Farthing, M.J., Octreotide in the treatment of refractory diarrhoea and intestinal

fistulae. Gut, 1994. 35 (suppl 3)(3 suppl): p. s5–10.

545. Martelli, L., et al., Evaluation of the efficacy of octreotide LAR in the treatment of

Crohn's disease associated refractory diarrhea. Scand J Gastroenterol, 2017. 52(5): p. 564-569.

546. Yang, A., J. Brown, and E. Mak, Persistent Diarrhea after Celiac Plexus Block in a

Pancreatic Cancer Patient: Case Report and Literature Review. J Palliat Med, 2016. 19(1):

p. 83-6.

547. Mercadante, S. and G. Porzio, Octreotide for malignant bowel obstruction: twenty

years after. Critical Reviews inOncology/Hematology, 2012. 83(3): p. 388-92.

548. Ripamonti, C. and S. Mercadante, How to use octreotide for malignant bowel

obstruction. Journal of Supportive Oncology, 2004. 2(4): p. 357-64.

549. Birch, E., D. Jenkins, and S. Noble, Treatment of painful hypertrophic osteoarthropathy associated with non-small cell lung cancer with octreotide: a case

report and review of the literature. BMJ Support Palliat Care, 2011. 1(2): p. 189-92.

550. Cairns, W. and R. Malone, Octreotide as an agent for the relief of malignant ascites

in palliative care patients. Palliative Medicine, 1999. 13: p. 429–430.

551. Harvey, M. and R. Dunlop, Octreotide and the secretory effects of advanced cancer.


552. Kalambokis, G., et al., Renal effects of treatment with diuretics, octreotide or both,

in non-azotemic cirrhotic patients with ascites. Nephrology, Dialysis, Transplantation,

2005. 20(8): p. 1623–9.

553. Hudson, E., et al., Successful treatment of bronchorrhea with octreotide in a patient with adenocarcinoma of the lung. Journal of Pain and Symptom Management, 2006.

32(3): p. 200–2.

554. Pahuja, M., R.W. Shepherd, and L.J. Lyckholm, The use of octreotide to manage

symptoms of bronchorrhea: a case report. J Pain Symptom Manage, 2014. 47(4): p. 814-

8.

555. Lamberts, S.W.J., et al., Octreotide. New England Journal of Medicine, 1996. 334(4):

p. 246–254.

556. Gyr, K. and R. Meier, Pharmacodynamic effects of sandostatin in the

gastrointestinal tract. Digestion, 1993. 54: p. 14–19.

557. Davies, R., et al., Somatostatin analogues in diabetes mellitus. Diabetic Medicine, 1989. 6: p. 103–111.

558. Lunetta, M., et al., Effects of octreotide on glycaemic control, glucose disposal,

hepatic glucose production and counterregulatory hormone secretion in type 1 and type

2 insulin treated diabetic patients. Diabetes Research and Clinical Practice, 1997. 38: p.

81–89.



Seite 30 von 39

559. Mercadante, S., Tolerability of continuous subcutaneous octreotide used in

combination with other drugs. Journal of Palliative Care, 1995. 11 (4)(4 ): p. 14–16.

560. Ludlam, W.H. and L. Anthony, Safety review: dose optimization of somatostatin analogs in patients with acromegaly and neuroendocrine tumors. Adv Ther, 2011.

28(10): p. 825-41.

561. Harris, A. and J. Redfern, Octreotide treatment of carcinoid syndrome: analysis of

published dose-titration data. Alimentary Pharmacology and Therapeutics, 1995. 9: p.

387–394.

562. Maroun, J.A., et al., Prevention and management of chemotherapy-induced

diarrhea in patients with colorectal cancer: a consensus statement by the Canadian

Working Group on Chemotherapy-Induced Diarrhea. Current Oncology, 2007. 14(1): p.

13-20.

563. Cello, J., et al., Effect of octreotide on refractory AIDS-associated diarrhea. A prospective, multicenter clinical trial. Annals of Internal Medicine, 1991. 115: p. 705–

710.

564. Stahl, S., Antipsychotic agents, in Essential Psychopharmacology: Neuroscientifc

Basis and Practical Applications. 2013, Cambridge University Press: USA. p. 129-236.

565. Hedges, D., K. Jeppson, and P. Whitehead, Antipsychotic medication and seizures: a

review. Drugs Today (Barc), 2003. 39(7): p. 551-7.

566. Tollefson, G., et al., Olanzapine versus haloperidol in the treatment of

schizophrenia and schizoaffective and schizophreniform disorders: results of an

international collaborative trial. American Journal of Psychiatry, 1997. 154: p. 457–465. 567. Conley, R. and H. Meltzer, Adverse events related to olanzapine. Journal of Clinical

Psychiatry, 2000. 61: p. 26–29.

568. Worrel, J.A., et al., Atypical antipsychotic agents: a critical review. American Journal

of Health System Pharmacy, 2000. 57(3): p. 238–55.

569. Geddes, J., et al., Atypical antipsychotics in the treatment of schizophrenia:

systematic overview and meta-regression analysis. British Medical Journal, 2000. 321: p.

1371–1376.

570. Beasley, C., G. Tollefson, and T. Tran, Efficacy of olanzapine: an overview of pivotal

clinical trials. Journal of Clinical Psychiatry, 1997. 58 (suppl 10): p. 7–12.

571. Elsayem, Subcutaneous olanzapine for hyperactive or mixed delirium in patients with advanced cancer: a preliminary study. Journal of Pain and Symptom Management,

2010. 40: p. 774-782.

572. Chiu, L., et al., Efficacy of olanzapine for the prophylaxis and rescue of

chemotherapy-induced nausea and vomiting (CINV): a systematic review and meta-

analysis. Support Care Cancer, 2016. 24(5): p. 2381-2392.

573. Fonte, C., S. Fatigoni, and F. Roila, A review of olanzapine as an antiemetic in

chemotherapy-induced nausea and vomiting and in palliative care patients. Crit Rev

Oncol Hematol, 2015. 95(2): p. 214-21.

574. MacKintosh, D., Olanzapine in the Management of Difficult to Control Nausea and

Vomiting in a Palliative Care Population: A Case Series. J Palliat Med, 2016. 19(1): p. 87-90.

575. Mukhopadhyay, S., et al., Role of olanzapine in chemotherapy-induced nausea and

vomiting on platinum-based chemotherapy patients: a randomized controlled study.

Support Care Cancer, 2017. 25(1): p. 145-154.

576. Nakagaki, M., et al., A randomized trial of olanzapine versus palonosetron versus

infused ondansetron for the treatment of breakthrough chemotherapy-induced nausea



Seite 31 von 39

and vomiting in patients undergoing hematopoietic stem cell transplantation. Support

Care Cancer, 2017. 25(2): p. 607-613.

577. Kato, M. and C.M. Chang, Augmentation treatments with second-generation antipsychotics to antidepressants in treatment-resistant depression. CNS Drugs, 2013.

27 Suppl 1: p. S11-9.

578. Kalso, E., Oxycodone. Journal of Pain and Symptom Management, 2005. 29 (suppl

5)(5 suppl): p. s47–s56.

579. Schmidt-Hansen, M., et al., Oxycodone for cancer-related pain. Cochrane Database

Syst Rev, 2015(2): p. Cd003870.

580. Ma, H., et al., The Adverse Events of Oxycodone in Cancer-Related Pain: A

Systematic Review and Meta-Analysis of Randomized Controlled Trials. Medicine

(Baltimore), 2016. 95(15): p. 1-9.

581. Gaspari, S., et al., RGS9-2 Modulates Responses to Oxycodone in Pain-Free and Chronic Pain States. Neuropsychopharmacology, 2017. 42(7): p. 1548-1556.

582. Nakamura, A., et al., Differential activation of the μ-opioid receptor by oxycodone

and morphine in pain-related brain regions in a bone cancer pain model. Br J Pharmacol,

2013. 168(2): p. 375-88.

583. Lemberg, K.K., et al., Antinociception by spinal and systemic oxycodone: why does

the route make a difference? In vitro and in vivo studies in rats. Anesthesiology, 2006.

105(4): p. 801-12.

584. Kalso, E., et al., Morphine and oxycodone in the management of cancer pain:

plasma levels determined by chemical and radioreceptor assays. Pharmacology and Toxicology, 1990. 67(4): p. 322–8.

585. Lauretti, G.R., G.M. Oliveira, and N.L. Pereira, Comparison of sustained-release

morphine with sustained-release oxycodone in advanced cancer patients. British Journal

of Cancer, 2003. 89(11): p. 2027–30.

586. Heiskanen, T. and E. Kalso, Controlled-release oxycodone and morphine in cancer

related pain. Pain, 1997. 73: p. 37–45.

587. Mucci-LoRusso, P., et al., Controlled-release oxycodone compared with controlled-

release morphine in the treatment of cancer pain: a randomized, double-blind, parallel-

group study. European Journal of Pain, 1998. 2: p. 239–249.

588. Kalso, E. and A. Vainio, Morphine and oxycodone in the management of cancer pain. Clinical Pharmacology and Therapeutics, 1990. 47: p. 639–646.

589. Bruera, E., et al., Randomized, double-blind, cross-over trial comparing safety and

efficacy of oral controlled-release oxycodone with controlled-release morphine in

patients with cancer pain. Journal of Clinical Oncology, 1998. 16: p. 3222–3229.

590. Curtis, G.B., et al., Relative potency of controlled-release oxycodone and controlled-

release morphine in a postoperative pain model. European Journal of Clinical

Pharmacology, 1999. 55(6): p. 425–9.

591. Kalso, E., et al., Intravenous morphine and oxycodone for pain after abdominal

surgery. Acta anaesthesiologica Scandinavica, 1991. 35(7): p. 642–6.

592. Beaver, W.T., et al., Analgesic studies of codeine and oxycodone in patients with cancer. II. Comparisons of intramuscular oxycodone with intramuscular morphine and

codeine. Journal Pharmacology and Experiemental Therapeutics, 1978. 207(1): p. 101–8.

593. Silvasti, M., et al., Comparison of analgesic efficacy of oxycodone and morphine in

postoperative intravenous patient-controlled analgesia. Acta anaesthesiologica

Scandinavica, 1998. 42(5): p. 576–80.



Seite 32 von 39

594. Leow, K., et al., Single-dose and steady-state pharmacokinetics and

pharmacodynamics of oxycodone in patients with cancer. Clinical Pharmacology and

Therapeutics, 1992. 52: p. 487–495. 595. Poyhia, R., et al., The pharmacokinetics and metabolism of oxycodone after

intramuscular and oral administration to healthy subjects. British Journal of Clinical

Pharmacology, 1992. 33: p. 617–621.

596. Leppert, W., Role of oxycodone and oxycodone/naloxone in cancer pain

management. Pharmacological Reports, 2010. 62(4): p. 578-91.

597. Reid, C.M., et al., Oxycodone for cancer-related pain: meta-analysis of randomized

controlled trials. Archives of Internal Medicine, 2006. 166(8): p. 837-43.

598. Lugo, R.A. and S.E. Kern, The pharmacokinetics of oxycodone. Journal of Pain and

Palliative Care Pharmacotherapy, 2004. 18 (4)(4): p. 17–30.

599. NPSA (National Patient Safety Agency). Reducing risk of overdose with midazolam injection in adults. Rapid response report 11. 2008; Available from:

www.nrls.npsa.nhs.uk/resources/?entryid45=59896.

600. NPSA (National Patient Safety Agency). Ensuring safer practice with high dose

ampoules of diamorphine and morphine. Safer Practice Notice. 295. 2006 [cited 295;

Available from: www.npsa.nhs.uk/resources.

601. Gardiner, P., Compatibility of an injectable oxycodone formulation with typical

diluents, syringes, tubings, infusion bags and drugs for potential co-administration.

Hospital Pharmacist 2003. 10: p. 354–361.

602. Hines, S. and S. Pleasance, Compatibility of an injectable high strength oxycodone formulation with typical diluents, syrings, tubings and infusion bags and drugs for

potential co-administration. European Journal of Hospital Pharmacy Practice, 2009. 15:

p. 32-38.


(Dilaudid IR) in subjects with moderate hepatic impairment. Proc West Pharmacol Soc,

2001. 44: p. 83-4.


(Dilaudid IR) in subjects with renal impairment. Proc West Pharmacol Soc, 2001. 44: p.

81–2.

605. Kim, J.W., et al., Proton pump inhibitors as a risk factor for recurrence of Clostridium difficile-associated diarrhea. World Journal of Gastroenterology, 2010.

16(28): p. 3573-7.

606. Garey, K.W., et al., Meta-analysis to assess risk factors for recurrent Clostridium

difficile infection. Journal of Hospital Infection, 2008. 70(4): p. 298-304.

607. Cunningham, R. and S. Dial, Is over-use of proton pump inhibitors fuelling the

current epidemic of Clostridium difficile-associated diarrhoea? Journal of Hospital

Infection, 2008. 70(1): p. 1-6.

608. Cadle, R.M., et al., Association of proton-pump inhibitors with outcomes in

Clostridium difficile colitis. American Journal of Health System Pharmacy, 2007. 64(22):

p. 2359-63. 609. Yearsley, K.A., et al., Proton pump inhibitor therapy is a risk factor for Clostridium

difficile-associated diarrhoea. Alimentary Pharmacology and Therapeutics, 2006. 24(4):

p. 613-9.

610. Dial S, etc, and etc, Use of gastric acid suppressive agents and the risk of

community acquired Clostridium difficile-associated diarrhoea. Journal of the American

Medical Association., 2005. 294: p. 2984-2995.



Seite 33 von 39

611. Jump, R.L., M.J. Pultz, and C.J. Donskey, Vegetative Clostridium difficile survives in

room air on moist surfaces and in gastric contents with reduced acidity: a potential

mechanism to explain the association between proton pump inhibitors and C. difficile-associated diarrhea? Antimicrobial Agents and Chemotherapy, 2007. 51(8): p. 2883-7.

612. Kwok, C.S., et al., Risk of Clostridium difficile infection with acid suppressing drugs

and antibiotics: meta-analysis. American Journal of Gastroenterology, 2012. 107(7): p.

1011-9.

613. MHRA. Clopidogrel and proton pump inhibitors: interaction - updated advice. Drug

Safety Update 3 (Sept) 4. 2010; Available from:

www.mhra.gov.uk/home/idcplg?IdcService=GET_FILE&dDocName=CON084657&Revisio

nSelectionMethod=LatestReleased.

614. Schonhofer, P., B. Werner, and U. Troger, Ocular damage associated with proton

pump inhibitors. British Medical Journal, 1997. 314: p. 1805. 615. Schonhofer, P., Intravenous omeprazole and blindness. Lancet, 1994. 343: p. 665.

616. Koop, H., et al. Gastroösophageale Refluxkrankkheit unter Federführung Deutschen

Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS).

2014 14. Juni 2014 AWMF-Registernummer: 021/013]; Available from:

http://www.awmf.org/uploads/tx_szleitlinien/021-013l_S2k_Refluxkrankheit_2014-

05.pdf.

617. NICE. Gastro-oesophageal reflux disease and dyspepsia in adults: investigation and

management. Clinical Guideline 2014 2014 [cited 2017 February]; CG184:[Available

from: https://www.nice.org.uk/guidance/cg184. 618. Zylicz, Z. and A. van Sorge, Rectal omeprazole in the treatment of reflux pain in

esophageal cancer. Journal of Pain and Symptom Management, 1998. 15: p. 144–145.

619. Desmidts T and Constans T, Subcutaneous infusion of esomeprazole in elderly

patients in palliative care: A report of two cases. Journal of the American Geriatrics

Society, 2009. 57: p. 1724-5.

620. Agar, M., et al., The use of subcutaneous omeprazole in the treatment of dyspepsia

in palliative care patients. Journal of Pain and Symptom Management, 2004. 28(6): p.

529–31.

621. Janssen, P.A., Pirinitramide (R 3365), a potent analgesic with unusual chemical

structure. J Pharm Pharmacol, 1961. 13: p. 513-30. 622. Kay, B., A clinical investigation of piritramide in the treatment of postoperative

pain. Br J Anaesth, 1971. 43(12): p. 1167-71.

623. Gibbs, D. and N. Pickler, Piritramide – a new long lasting analgesic. Anaesth

Intensive Care, 1982. 1: p. 308-314.

624. Janssen, P.A., Potent, new analgesics, tailor-made for different purposes. Acta

Anaesthesiol Scand, 1982. 26(3): p. 262-8.

625. Kumar, N. and D.J. Rowbotham, Piritramide. Br J Anaesth, 1999. 82(1): p. 3-5.

626. Bouillon, T., P. Groeger, and D. Kietzmann, The pharmacokinetics of piritramide

after prolonged administration to intensive care patients. Eur J Anaesthesiol, 2004.

21(9): p. 673-8. 627. Kietzmann, D., et al., Pharmacodynamic modelling of the analgesic effects of

piritramide in postoperative patients. Acta Anaesthesiol Scand, 1997. 41(7): p. 888-94.

628. Carrasco, J.L. and C. Sandner, Clinical effects of pharmacological variations in

selective serotonin reuptake inhibitors: an overview. International Journal of Clinical

Practice, 2005. 59(12): p. 1428-34.



Seite 34 von 39

629. Haddad, P.M., Antidepressant discontinuation syndromes: Clinical relevance,

prevention and management. Drug Safety, 2001. 24(3): p. 183-97.

630. Hashimoto, K., Sigma-1 receptors and selective serotonin reuptake inhibitors: clinical implications of their relationship. Central Nervous System Agents in Medicinal

Chemistry, 2009. 9(3): p. 197-204.

631. Preskorn, S.H., Clinically relevant pharmacology of selective serotonin reuptake

inhibitors. An overview with emphasis on pharmacokinetics and effects on oxidative

drug metabolism. Clinical Pharmacokinetics, 1997. 32 Suppl 1: p. 1-21.

632. Rao, N., The clinical pharmacokinetics of escitalopram. Clinical Pharmacokinetics,

2007. 46(4): p. 281-90.

633. Kaye, C.M., et al., A review of the metabolism and pharmacokinetics of paroxetine

in man. Acta Psychiatrica Scandinavica Supplementum, 1989. 350: p. 60-75.

634. Hiemke, Pharmacokinetics of selective serotonin reuptake inhibitors. Pharmacology and Therapeutics, 2000. 85(1): p. 11-28.

635. Garnock-Jones, K.P. and P.L. McCormack, Escitalopram: a review of its use in the

management of major depressive disorder in adults. CNS Drugs, 2010. 24(9): p. 769-96.

636. Paton, C. and I.N. Ferrier, SSRIs and gastrointestinal bleeding. British Medical

Journal, 2005. 331(7516): p. 529–30.

637. vanWalraven, C., et al., Inhibition of serotonin reuptake by antidepressants and

upper gastrointestinal bleeding in elderly patients: retrospective cohort study. British

Medical Journal, 2001. 323: p. 655–657.

638. FDA, Celexa (citalopram hydrobromide) Revised recommendations, potential risk of abnormal heart rhythms. Drug safety communication, 2012: p.

http://www.fda.gov/Safety/MedWatch/

639. Isbister, G.K., et al., Relative toxicity of selective serotonin reuptake inhibitors

(SSRIs) in overdose. Journal of Toxicology and Clinical Toxicology, 2004. 42(3): p. 277–85.

640. Castro, V.M., et al., QT interval and antidepressant use: a cross sectional study of

electronic health records. British Medical Journal, 2013. 346: p. f288.

641. MHRA, Citalopram and escitalopram: QT interval prolongation - new maximum

daily dose restrictions (including in elderly patients), contraindications, and warnings.

Drug Safety Update, 2011. 5(5): p. A1.

642. Lundbeck, Zusammenhang von CIPRAMIL® (Citalopramhydrobromid/Citalopramhydrochlorid) mit dosisabhängiger QT-Intervall-

Verlängerung in Rote Hand Brief. 2011.

643. Mayo, M.J., et al., Sertraline as a first-line treatment for cholestatic pruritus.

Hepatology, 2007. 45(3): p. 666–74.

644. Wortzel, H.S., et al., Pathological laughing and crying : epidemiology,

pathophysiology and treatment. CNS Drugs, 2008. 22(7): p. 531-45.

645. De Schryver, A.M., M. Samsom, and A.I. Smout, Effects of a meal and bisacodyl on

colonic motility in healthy volunteers and patients with slow-transit constipation.

Digestive Diseases Sciences, 2003. 48(7): p. 1206–12.

646. Larkin, P.J., et al., The management of constipation in palliative care: clinical practice recommendations. Palliative Medicine, 2008. 22(7): p. 796–807.

647. Hawley, P.H. and J.J. Byeon, A comparison of sennosides-based bowel protocols

with and without docusate in hospitalized patients with cancer. Journal of Palliative

Medicine, 2008. 11(4): p. 575-81.

648. NICE, Palliative cancer care - constipation. Clinical Knowledge Summaries, 2013.



Seite 35 von 39

649. Sykes, N., A clinical comparison of laxatives in a hospice. Palliative Medicine, 1991.

5: p. 307–14.

650. Twycross, R.G., et al., Sodium picosulfate in opioid-induced constipation: results of an open-label, prospective, dose-ranging study. Palliative Medicine, 2006. 20: p. 419–

423.

651. Tzschentke, T.M., T. Christoph, and B.Y. Kogel, The mu-opioid receptor

agonist/noradrenaline reuptake inhibition (MOR-NRI) concept in analgesia: the case of

tapentadol. CNS Drugs, 2014. 28(4): p. 319-29.

652. Hoy, S.M., Tapentadol extended release: in adults with chronic pain. Drugs, 2012.

72(3): p. 375-93.

653. Schroder, W., et al., Synergistic interaction between the two mechanisms of action

of tapentadol in analgesia. J Pharmacol Exp Ther, 2011. 337(1): p. 312-20.

654. Etropolski, M., et al., Comparable efficacy and superior gastrointestinal tolerability (nausea, vomiting, constipation) of tapentadol compared with oxycodone hydrochloride.

Adv Ther, 2011. 28(5): p. 401-17.

655. Galvez, R., et al., Tapentadol prolonged release versus strong opioids for severe,

chronic low back pain: results of an open-label, phase 3b study. Adv Ther, 2013. 30(3): p.

229-59.

656. Kress, H.G., et al., Tapentadol prolonged release for managing moderate to severe,

chronic malignant tumor-related pain. Pain Physician, 2014. 17(4): p. 329-43.

657. Cepeda, M.S., et al., Comparison of opioid doctor shopping for tapentadol and

oxycodone: a cohort study. J Pain, 2013. 14(2): p. 158-64. 658. Sanchez Del Aguila, M.J., et al., Practical considerations for the use of tapentadol

prolonged release for the management of severe chronic pain. Clin Ther, 2015. 37(1): p.

94-113.

659. Imanaka, K., et al., Ready conversion of patients with well-controlled, moderate to

severe, chronic malignant tumor-related pain on other opioids to tapentadol extended

release. Clin Drug Investig, 2014. 34(7): p. 501-11.

660. Jasinski, D.R. and K.L. Preston, Evaluation of tilidine for morphine-like subjective

effects and euphoria. Drug Alcohol Depend, 1986. 18(3): p. 273-92.

661. Vollmer, K., Pharmaokinetische Grundlagen des Valoron-N-Prinzips. Fortschritte der

Medizin, 1988. 29: p. 539-596. 662. Brennscheidt, U., K.U. Seiler, and P. Thomann, Pharmacokinetics of nortilidine and

naloxone after administration of tilidine/naloxone solution or tilidine/naloxone

sustained release tablets. Arzneimittelforschung, 2000. 50(11): p. 1015-22.

663. Thierry, C., J.-M. Boeynaems, and M. Paolo, Actions of tilidine and nortilidine on

cloned opioid receptors. European Journal of Pharmacology, 2005. 506(3): p. 205-208.

664. Hajda, J., et al., Sequential first-pass metabolism of nortilidine: the active

metabolite of the synthetic opioid drug tilidine. The Journal of Clinical Pharmacology,

2002. 42(11): p. 1257-1261.

665. Grond, S. and A. Sablotzki, Clinical pharmacology of tramadol. Clinical

Pharmacokinetics, 2004. 43(13): p. 879–923. 666. Dickman, A., Tramadol: a review of this atypical opioid. European Journal of

Palliative Care, 2007. 14(5): p. 181–185.

667. Vickers, M., et al., Tramadol: pain relief by an opioid without depression of

respiration. Anaesthesia, 1992. 47: p. 291–296.

668. Gibson, T., Pharmacokinetics, efficacy, and safety of analgesia with a focus on

tramadol HCl. American Journal of Medicine, 1996. 101 (suppl 1A)(suppl 1A): p. 47s–53s.



Seite 36 von 39

669. Mercadante, S., et al., Randomized double-blind, double-dummy crossover clinical

trial of oral tramadol versus rectal tramadol administration in opioid-naive cancer

patients with pain. Supportive Care in Cancer, 2005. 13(9): p. 702–7. 670. Lintz, W., et al., Pharmacokinetics of tramadol and bioavailability of enteral

tramadol formulations. 3rd Communication: suppositories. Arzneimittelforschung, 1998.

48(9): p. 889–99.

671. FDA. Drug safety communication: FDA restricts use of prescription codeine pain and

cough medicines and tramadol pain medicines in children; recommends against use in

breastfeeding women. . Drug safety communication 2017 [cited 2017; Available from:

www.fda.gov/downloads/drugs/drugsafety/ucm553814.pdf.

672. Park, S.H., R.C. Wackernah, and G.L. Stimmel, Serotonin syndrome: is it a reason to

avoid the use of tramadol with antidepressants? J Pharm Pract, 2014. 27(1): p. 71-8.

673. Pilgrim, J.L., D. Gerostamoulos, and O.H. Drummer, Deaths involving contraindicated and inappropriate combinations of serotonergic drugs. Int J Legal Med,

2011. 125(6): p. 803-15.

674. Saarikoski, T., et al., Rifampicin markedly decreases the exposure to oral and

intravenous tramadol. Eur J Clin Pharmacol, 2013. 69(6): p. 1293-301.

675. Laugesen, S., et al., Paroxetine, a cytochrome P450 2D6 inhibitor, diminishes the

stereoselective O-demethylation and reduces the hypoalgesic effect of tramadol. Clin

Pharmacol Ther, 2005. 77(4): p. 312–23.

676. De Witte, J.L., et al., The analgesic efficacy of tramadol is impaired by concurrent

administration of ondansetron. Anesthesia and Analgesia, 2001. 92(5): p. 1319–21. 677. Leppert, W. and J. Luczak, The role of tramadol in cancer pain treatment--a review.

Supportive Care in Cancer, 2005. 13(1): p. 5–17.

678. Grond, S., et al., High-dose tramadol in comparison to low-dose morphine for

cancer pain relief. Journal of Pain and Symptom Management, 1999. 18(3): p. 174–9.

679. Osipova, N., et al., Analgesic effect of tramadol in cancer patients with chronic pain:

A comparison with prolonged-action morphine sulfate. Current Therapeutic Research,

1991. 50: p. 812–815.

680. Mannucci, P.M., Hemostatic drugs. N Engl J Med, 1998. 339(4): p. 245-53.

681. Andersson L, et al., Special considerations with regard to the dosage of tranexamic

acid in patients with chronic renal diseases. Urological Research, 1978. 6(2): p. 83-8. 682. Lacy, C., etc, and etc, eds. Lexi-Comp's Drug Information Handbook. 11 ed. 2003,

Lexi-Comp and the American Pharmaceutical Association: Hudson, Ohio.

683. KG, M.P.G.C. Fachinformation Cyklokapron Filmtabletten. 2013 [cited 2014

05.10.2014]; Available from: www.fachinfo.de.

684. Schultz, M. and H. van der Lelie, Microscopic haematuria as a relative

contraindication for tranexamic acid. British Journal of Haematology, 1995. 89(3): p.

663–4.

685. Regnard, C. and W. Makin, Management of bleeding in advanced cancer: a flow

diagram. Palliative Medicine, 1992. 6: p. 74–78.

686. Kochhar, R., et al., Rectal sucralfate in radiation proctitis. Lancet, 1988. 332: p. 400. 687. Krempl, G.A. and A.D. Noorily, Use of oxymetazoline in the management of

epistaxis. Ann Otol Rhinol Laryngol, 1995. 104(9 Pt 1): p. 704-6.

688. Recka, K., M. Montagnini, and C.A. Vitale, Management of bleeding associated with

malignant wounds. Journal Palliative of Medicine, 2012. 15(8): p. 952-4.

689. Hedges SJ, etc, and etc, Evidence-based treatment recommendations for uremic

bleeding. Nature Clinical Practice Oncology, 2006. 3(3): p. 138-153.



Seite 37 von 39

690. Cihoric, N., et al., Clinically significant bleeding in incurable cancer patients:

effectiveness of hemostatic radiotherapy. Radiation Oncololgy, 2012. 7: p. 132.

691. Roberts, I., et al., The CRASH-2 trial: a randomised controlled trial and economic evaluation of the effects of tranexamic acid on death, vascular occlusive events and

transfusion requirement in bleeding trauma patients. Health Technol Assess, 2013.

17(10): p. 1-79.

692. Rankin, E., R. Rubens, and J. Reidy, Transcatheter embolisation to control severe

bleeding in fungating breast cancer. European Journal of Surgical Oncology, 1988. 14: p.

27–32.

693. McCormack, P.L., Tranexamic acid: a review of its use in the treatment of

hyperfibrinolysis. Drugs, 2012. 72(5): p. 585-617.

694. Dunn, C.J. and K.L. Goa, Tranexamic acid: a review of its use in surgery and other

indications. Drugs, 1999. 57(6): p. 1005-32. 695. Palliativedrugs.com, Topical Tranexamic Acid - What do you do? . Survey, 2013.

March-April: p. Available from www.palliativedrugs.com.

696. McElligott, E., C. Quigley, and G. Hanks, Tranexamic acid and rectal bleeding.

Lancet, 1991. 337: p. 431.

697. Solomonov, A., et al., Pulmonary hemorrhage: A novel mode of therapy. Respir

Med, 2009. 103(8): p. 1196-200.

698. Hankerson, M.J., et al., Nebulized Tranexamic Acid as a Noninvasive Therapy for

Cancer-Related Hemoptysis. J Palliat Med, 2015. 18(12): p. 1060-2.

699. deBoer, W., e. al, and e. al, Tranexamic acid treatment of haemothorax in two patients with malignant mesothelioma. Chest, 1991. 100: p. 847–848.

700. Dean, A. and P. Tuffin, Fibrinolytic inhibitors for cancer-associated bleeding

problems. Journal of Pain and Symptom Management, 1997. 13: p. 20–24.

701. Loscher, W., Basic pharmacology of valproate: a review after 35 years of clinical use

for the treatment of epilepsy. CNS Drugs, 2002. 16(10): p. 669-94.

702. Chang, P., M.C. Walker, and R.S. Williams, Seizure-induced reduction in PIP3 levels

contributes to seizure-activity and is rescued by valproic acid. Neurobiol Dis, 2014. 62: p.

296-306.

703. Kay, H.Y., et al., M-current preservation contributes to anticonvulsant effects of

valproic acid. J Clin Invest, 2015. 125(10): p. 3904-14. 704. Snare AJ, Sodium Valproate. Retrospective analysis of neuropathic pain control in

patients with advanced cancer. Journal of Pharmacy Technology, 1993. 9: p. 114-117.

705. Perucca, E., Pharmacological and therapeutic properties of valproate: a summary

after 35 years of clinical experience. CNS Drugs, 2002. 16(10): p. 695-714.

706. Mancl EE and Gidal BE, The effect of carbapenem antibiotics on plasma

concentrations of valproic acid. Annals of Pharmacotherapy, 2009. 43(12): p. 2082-2087.

707. Kwan, P. and M.J. Brodie, Effectiveness of first antiepileptic drug. Epilepsia, 2001.

42(10): p. 1255-60.

708. Trinka, E., et al., Efficacy and safety of intravenous valproate for status epilepticus:

a systematic review. CNS Drugs, 2014. 28(7): p. 623-39. 709. Hardy, J.R., et al., A phase II study to establish the efficacy and toxicity of sodium

valproate in patients with cancer-related neuropathic pain.[see comment]. Journal of

Pain & Symptom Management, 2001. 21(3): p. 204-9.

710. Beique, J.C., et al., Affinities of venlafaxine and various reuptake inhibitors for the

serotonin and norepinephrine transporters. European Journal of Pharmacology, 1998.

349(1): p. 129-32.



Seite 38 von 39

711. Melichar, J., et al., Venlafaxine occupation at the noradrenaline reuptake site: in-

vivo determination in healthy volunteers. Journal of Psychopharmacology, 2001. 15: p.

9–12. 712. AKDÄ and KBV Venlafaxin. Wirkstoff AKTUELL, 2008.

713. Akers, K.S., et al., Colistin pharmacokinetics in burn patients during continuous

venovenous hemofiltration. Antimicrob Agents Chemother, 2015. 59(1): p. 46-52.

714. Baxter, K. Stockley's Drug Interactions (online edition). 2013; Available from:

www.medicinescomplete.com.

715. Borgeat, A. and H.-R. Stimemann, Ondansetron is effective to treat spinal or

epidural morphine-induced pruritus. Anesthesiology, 1999. 90: p. 432–436.

716. Kyriakides, K., S. Hussain, and G. Hobbs, Management of opioid-induced pruritus: a

role for 5HT antagonists? British Journal of Anaesthesia, 1999. 82: p. 439–441.

717. Kiesewetter, B. and M. Raderer, Ondansetron for diarrhea associated with neuroendocrine tumors. N Engl J Med, 2013. 368(20): p. 1947-8.

718. To, T.H., et al., The role of ondansetron in the management of cholestatic or uremic

pruritus--a systematic review. J Pain Symptom Manage, 2012. 44(5): p. 725-30.

719. Saito, M., et al., Palonosetron plus dexamethasone versus granisetron plus

dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-

blind, double-dummy, randomised, comparative phase III trial. Lancet Oncology, 2009.

10(2): p. 115-24.

720. Baguley, W., et al., Cardiac dysrhythmias associated with the intravenous

administration of ondansetron and metoclopramide. Anesthesia and Analgesia, 1997. 84: p. 1380–1381.

721. Goodin, S. and R. Cunningham, 5-HT3-receptor antagonists for the treatment of

nausea and vomiting: a reappraisal of their side-effect profile. The Oncologist, 2002. 7:

p. 424–436.

722. Boccia, R.V., et al., Efficacy and tolerability of transdermal granisetron for the

control of chemotherapy-induced nausea and vomiting associated with moderately and

highly emetogenic multi-day chemotherapy: a randomized, double-blind, phase III study.

Support Care Cancer, 2011. 19(10): p. 1609-17.

723. Perez, E.A., et al., Efficacy and safety of different doses of granisetron for the

prophylaxis of cisplatin-induced emesis. Support Care Cancer, 1997. 5(1): p. 31–7. 724. Perez, E., et al., Efficacy and safety of oral granisetron versus IV ondansetron in

prevention of moderately emetogenic chemotherapy-induced nausea and vomiting.

Proceedings of the American Society of Clinical Oncology, 1997. 16: p. 149.

725. Gralla, R., et al., Can an oral antiemetic regimen be as effective as intravenous

treatment against cisplatin: results of a 1054 patient randomized study of oral

granisetron versus IV ondansetron. Proceedings of the American Society of Clinical

Oncology, 1997. 16: p. 178.

726. Minami, M., Granisetron: is there a dose-response effect on nausea and vomiting?

Cancer Chemotherapy and Pharmacology, 2003. 52: p. 89–98.

727. Gurpide, A., et al., Randomized crossover pharmacokinetic evaluation of subcutaneous versus intravenous granisetron in cancer patients treated with platinum-

based chemotherapy. Oncologist, 2007. 12(9): p. 1151-5.

728. Macario, A., et al., Improved outcome with chronic subcutaneous infusion of

odansetron for intractable nausea and vomiting. Anesthesia and Analgesia, 1996. 83(1):

p. 194-5.



Seite 39 von 39

729. Philpot, C.R., Ondansetron by subcutaneous infusion. Med J Aust, 1993. 159(3): p.

213.

730. Loughner, J.E., O. Abulafia, and O. Sahasrabudhe, Lack of vesicant activity of ondansetron. Ann Pharmacother, 1993. 27(9): p. 1140-1.

731. Furukawa, Low dosage tricyclic antidepressants for depression. Cochrane Database

of Systematic Reviews, 2009.

732. Magueur, E., et al., Pharmacokinetics of metoclopramide in patients with liver

cirrhosis. Br J Clin Pharmacol, 1991. 31(2): p. 185-7.

733 Twycross, R.G. and I. Back, Nausea and vomiting in advanced cancer. European

Journal of Palliative Care, 1998. 5: p. 39–45.

734 Ganzini, L., et al., The prevalence of metoclopramide-induced tardive dyskinesia

and acute extrapyramidal movement disorders. Arch Intern Med, 1993. 153(12): p.

1469-75.

23695 Literatur neue Nummerierung CR - Amazon …...©Elsevier GmbH. Alle Rechte vorbehalten. Rémi...

Documents

Transcript of 23695 Literatur neue Nummerierung CR - Amazon …...©Elsevier GmbH. Alle Rechte vorbehalten. Rémi...